1,2,4-TRIAZOLE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE
SAME
Technical Field
The present invention relates to a 1,2,4-triazole derivative or non-toxic salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient.
Background Art
Most nonsteroidal antiinflammatory agents are responsible for blocking the enzyme, cyclooxygenase (COX) or prostaglandin G/H synthase, thereby reducing inflammation, pain, or fever. In addition, they inhibit uterus contraction caused by hormones and also inhibit growth of several cancers. Cyclooxygenase-1 (COX-1) was first discovered in bovine. The COX-1 is constitutively expressed in a variety of cell types. Unlike the COX-1, cyclooxygenase-2 (COX-2) is a recently discovered isoform of cyclooxygenase that is easily inducible by mitogen, endotoxin, hormone, growth factor, or cytokine.
Prostaglandin is a potent mediator of various pathological and physiological processes. The COX-1 plays important physiological roles such as the release of endogenous prostaglandin, the maintenance of the shape, the function of stomach, and blood circulation in kidney. On the other hand, the COX-2 is induced by an inflammatory factor, hormone, growth factor, or cytokine. Therefore, the COX-2 is involved in pathological processes of prostaglandin unlike the constitutive COX-1. In this regard, selective inhibitors of the COX-2 produce fewer and less side effects in terms of action mechanism in comparison with conventional nonsteroidal antiinflammatory agents. In addition, they reduce inflammation, pain, and fever and inhibit uterus contraction caused by hormones and growth of several cancers. In particular, they are effective in decreasing side effects such as stomach toxicity and kidney toxicity. Still furthermore, they inhibit the synthesis of contractile prostanoid, thereby leading to suppression of the contraction of smooth muscles. Therefore, premature birth, menstrual irregularity, asthma, and eosinophilic disease can be prevented.

Recently, it was reported that nonsteroidal antiinflammatory agents are effective in treating large intestine cancer [European Journal of Cancer, Vol 37, p2302, 2001], prostate cancer [Urology, Vol 58, p127, 2001], and dementia [Exp. Opin. Invest. Drugs, Vol 9, p671, 2000].
In addition, it is anticipated that selective COX-2 inhibitors would be effective in treating osteoporosis and glaucoma. Utility of selective COX-2 inhibitors is well described in documents [John Vane, "Towards a Better Aspirin" in Nature, Vol.367, pp215-216, 1994; Bruno Battistini, Regina Botting and Y.S. Bakhle, "COX-1 and COX-2: Toward the Development of More Selective NSAIDs" in Drug News and Perspectives, Vol.7, pp501-512, 1994; David B. Reitz and Karen Seibert, "Selective Cyclooxygenase Inhibitors" in Annual Reports in Medicinal Chemistry, James A. Bristol, Editor, Vol. 30, pp179-188, 1995].
Various selective COX-2 inhibitors having different structures have been known. Among them, a selective COX-2 inhibitor having a diaryl heterocyclic structure, i.e. a tricyclic structure has been widely studied as a potent candidate. The diaryl heterocyclic structure has a central ring and a sulfonamide or methylsulfone group attached to one of the aryl rings. An initial substance having such diaryl heterocyclic structure is Dup697 [Bioorganic & Medicinal Chemistry Letters, Vol 5, p2123, 1995]. Since then, SC-58635 having a pyrazol ring (Journal of Medicinal Chemistry, Vol 40, p1347, 1997) and MK-966 having a furanone ring (WO 95/00501) were discovered as derivatives of the Dup697.
One selective COX-2 inhibitor, Celecoxib of formula 58 is disclosed in U.S. Patent No. 5,466,823. The Celecoxib is a substituted pyrazolyl benzenesulfonamide derivative.
Formula 58

(Formula 58 Removed)

Another selective COX-2 inhibitor, Rofecoxib of formula 59 is disclosed in WO 95/00501. The Rofecoxib has a diaryl heterocyclic structure with a central furanone ring.
Formula 59
(Formula 59 Removed)
Valdecoxib of formula 60 as another selective COX-2 inhibitor is disclosed in U.S. Patent No. 5,633,272. The Valdecoxib has a phenylsulfonamide moiety with a central isoxazole ring.
Formula 60
(Formula 60 Removed)
The selective COX-2 inhibitors of formulas 58 to 60 are effective inflammatory therapeutic agents with fewer and less side effects in comparison with conventional nonsteroidal antiinflammatory agents.
Disclosure of the Invention
An object of the present invention is to provide a 1,2,4-triazole derivative of formula 1 or a non-toxic salt thereof.
Another object of the present invention is to provide a method for preparing a 1,2,4-triazole derivative or a non-toxic salt thereof.
Another object of the present invention is to provide pharmaceutical compositions comprising a 1,2,4-triazole derivative or a non-toxic salt thereof as an active ingredient for the treatment of fever, pain, and inflammation.
Yet another object of the present invention is to provide a pharmaceutical composition comprising a 1,2,4-triazole derivative or a non-toxic salt thereof as an active ingredient for the treatment of cancers and dementia.
Best mode for carrying out the Invention
According to an aspect of the present invention, there is provided 1,2,4-triazole derivatives represented by formula 1: Formula 1
wherein:
R-i is a Cs-Ce cycloalkyl group; a C3-Ce cycloalkenyl group; a phenyl group; a phenyl group substituted with one or more selected from the group consisting of a CrC6 alkyl group, a C-i-C6 haloalkyl group, a C-i-Ce alkoxy group, a CrCe haloalkoxy group, a halogen group, an amino group, a monoalkylamino group, a dialkylamino group, a nitro group, and a cyano group; a styrenyl group; a C-i-Ce alkoxy styrenyl group; or a pyridyl group;
RZ is a methyl or amino group; and
A, B, C, and D are independently carbon or nitrogen;
or a non-toxic salt thereof.
The 1,2,4-triazole derivative of formula 1 may be present in the form of a non-toxic salt. The term, "non-toxic salt" as used herein refers
to a pharmaceutically acceptable, toxin-free salt, including an organic salt and an inorganic salt.
The Inorganic salt of the 1,2,4-triazoIe derivative of formula 1 includes an inorganic salt of aluminum, ammonium, calcium, copper, iron, lithium, magnesium, manganese, potassium, sodium, or zinc but is not limited thereto. An inorganic salt of ammonium, calcium, potassium, or sodium is preferable.
The organic salt of the 1,2,4-triazole derivative of formula 1
includes an organic amine salt of primary, secondary, or tertiary amine,
substituted amine that is present in nature, or cyclic amine, or a salt of a
basic ion exchange resin but is not limited thereto. Examples of the salt
of a basic ion exchange resin include, but are not limited to, a salt of
arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine,
diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol,
ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine,
N-methylglucamine, glucamine, glucosamine, histidine,
N-(2-hydroxyethyl)piperidine, N-(2-hydroxyethyl)pyrrolidine,
isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resin, procaine, purine, triethylamine, trimethylamine, and tripropylamine.
The 1,2,4-triazole derivative of formula 1 may be present in the form of an organic acid salt or an inorganic acid salt.
Examples of the organic acid salt or the inorganic acid salt of the 1,2,4-triazole derivative of formula 1 include, but are not limited to, a salt of acetic acid, adipic acid, aspartic acid, 1,5-naphthalene disulfonic acid, benzene sulfonic acid, benzoic acid, camphor sulfonic acid, citric acid, 1,2-ethane disulfonic acid, ethane sulfonic acid, ethylenediaminetetraacetic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, hydroiodic acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methane sulfonic acid, mucic acid, 2-naphthalenedisulfonic acid, nitric acid, oxalic acid, pentothenic acid, phosphoric acid, pivalric acid, propionic acid, salicylic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, p-toluene sulfonic acid, undecanoic acid, and 10-undecenoic acid. A salt of succinic acid, hydrobromic acid, hydrochloric acid, maleic acid, methanesulfonic acid, phosphoric acid, sulfuric acid, or tartaric acid is preferable.

A preferred group of the 1,2,4-triazole derivative of the present invention is as follows:
1-(4-methanesulfonylphenyl)-5-phenyl-3-trifluoromethyl-1H-[1,2,4]t riazole;
5-(4-bromophenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1 H-[1,2,4]triazole;
5-(3-bromophenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1 H-[1,2,4]triazole;
5-(4-fluorophenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1 H-[1,2,4]triazole;
5-(3,5-dichloro-4-methoxyphenyl)-1-(4-methanesuIfonylphenyl)-3-t rifluoromethyl-1 H-[1,2,4]triazole;
5-(4-chlorophenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1H-[1,2,4]triazole;
5-(3,4-dichlorophenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromet hyl-1H-[1,2,4]triazole;
5-(3,4-dimethoxyphenyl)-1-(4-methanesulfonylphenyl)-3-trifluorom ethyl-1H-[1,2,4]triazole;
5-(3,4-difluorophenyl)-1-(4-methanesulfonylphenyl)-3-trifluorometh yl-1H-[1,2,4]triazole;
1-(4-methanesulfonylphenyl)-5-(4-methoxyphenyl)-3-trifluorometh yl-1H-[1,2,4]triazole;
5-(3,4-dimethoxyphenyl)-1-(4-methanesulfonylphenyl)-3-trifluorom ethyl-1 H-[1,2,4]triazole;
1-(4-methanesulfonylphenyl)-5-p-tolyl-3-trifluoromethyl-1H-[1,2,4]tr iazole;
5-(3,4-dimethylphenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromet hyl-1H-[1,2,43triazole;
5-(3-chloro-4-methylphenyl)-1-(4-methanesulfonyIphenyl)-3-trifluor omethyl-1 H-[1,2,4]triazole;
5-(4-chloro-3-methylphenyl)-1-(4-methanesulfonylphenyl)-3-trifluor omethyl-1 H-[1,2,4]triazole;
5-(3-chloro-4-methoxyphenyl)-1-(4-methanesulfonylphenyl)-3-triflu oromethyl-1 H-[1,2,4]triazole;
5-(4-chloro-3-methoxyphenyl)-1-(4-methanesulfonylphenyl)-3-triflu oromethyl-1 H-[1,2,4]triazole;

5-(3-fluoro-4-methylphenyl)-1-(4-methanesulfonylphenyl)-3-trifluor omethyl-1 H-[1,2,4]triazole;
5-(4-fluoro-3-methylphenyl)-1-(4-methanesulfonylphenyl)-3-trifluor omethyl-1 H-[1,2,4]triazole;
5-(3-fiuoro-4-methoxyphenyl)-1-(4-methanesulfonylphenyl)-3-triflu oromethyl-1 H-[1,2,4]triazole;
1-(4-methanesulfonylphenyl)-3-trifluoromethyl-5-(4-trifIuoromethyl phenyl)-1H-[1,2,4]triazole;
5-(4-ethoxyphenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1H-[1,2,4]triazole;
1-(4-methanesulfonylphenyl)-5-(4-trifluoromethoxyphenyl)-3-trifluo romethyl-1 H-[1,2,4]triazole;
5-(4-t-butylphenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1H-[1,2,4]triazole;
5-(4-cyanophenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1H-[1,2,4]triazole;
5-[4-(N-methylamino)-phenyl]-1-(4-methanesulfonylphenyl)-3-triflu oromethyl-1 H-[1,2,4]triazole;
5-[4-(N,N-dimethylamino)-phenyl]-1-(4-methanesulfonylphenyl)-3-t rifluoromethyl-1 H-[1,2,4]triazole;
5-(4-aminophenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1H-[1,2,4]triazole;
5-(3-trifluoromethylphenyl)-1-(4-methanesulfonylphenyl)-3-trifluoro methyl-1H-[1,2,4]triazo!e;
5-(3-methoxyphenyl)-1-(4-methanesulfonylphenyl)-3-trifluorometh yl-1H-[1,2,4]triazole;
1 -(4-methanesulfonylphenyl)-5-m-tolyl-3-trifluoromethyl-1 H-[1,2,4]t riazole;
1 -(4-methanesulfonylphenyl)-5-o-tolyl-3-trifluoromethyl-1 H-[1,2,4]tr iazole;
5-(2-bromophenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1 H-[1,2,4]triazole;
5-(2-methoxyphenyl)-1-(4-methanesulfonylphenyl)-3-trifluorometh yl-1H-[1,2,4]triazole;
5-(2,4-difluorophenyl)-1-(4-methanesulfonylphenyl)-3-trifluorometh yl-1H-[1,2,4]triazole;

5-(2,5-difluorophenyl)-1-(4-methanesulfonylphenyl)-3-trifluorometh yl-1H-[1,2,4]triazole;
5-(2,4,5-trifluorophenyl)-1-(4-methanesulfonylphenyl)-3-trifluorome thyl-1H-[1,2,4]triazole;
5-(2,3-dichlorophenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromet hyl-1 H-[1,2,4]triazole;
5-(2,4-dichlorophenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromet hyl-1 H-[1,2,4]triazole;
5-(3,5-difluorophenyl)-1-(4-methanesulfonylphenyl)-3-trifluorometh yl-1H-[1,2,4]triazole;
5-(3,5-dimethoxyphenyl)-1-(4-methanesulfonylphenyl)-3-trifluorom ethyl-1H-[1,2,4]triazole;
5-(2,4-dimethoxypheny!)-1-(4-methanesulfonylphenyl)-3-trifluorom ethyl-1H-[1,2,4]triazoie;
5-(3,4,5-trimethoxyphenyl)-1-(4-methanesulfonylphenyl)-3-frifluoro methyl- 1H-[1,2,4]triazole;
5-(2-fluoro-4-trifluoromethylphenyl)-1-(4-methanesulfonylphenyl)-3 -trifluoromethyl-1 H-[1,2,4]triazole;
5-(2-chloro-4-nitrophenyl)-1-(4-methanesulfony!phenyl)-3-trifluoro methyl-1H-[1,2,4]triazole;
5-(2,4-dichloro-5-fluorophenyl)-1-(4-methanesulfonylphenyl)-3-trifl uoromethyl-1 H-[1,2,4Jtriazole;
5-(3-fluoro-4-methylphenyl)-1-(4-methanesulfonylphenyl)-3-trifluor omethyl-1H-[1,2,4]triazole;
5-benzo[1,3]dioxol-5-yl-1-(4-methanesulfonylphenyl)-3-trifluoromet hyl-1 H-[1,2,4]triazole;
5-methanesufonyl-2-[3-trifluoromethyl-5-(trifluoromethylpheny)-[1,2,4]triazole-1-yl]pyridine;
5-methanesulfonyl-2-[3-trifluoromethyl-5-(4-ethoxyphenyl)-[1,2,4]tr iazol-1-yl]pyridine;
5-methanesulfonyl-2-[3-trifluoromethyl-5-(4-trifluoromethoxyphenyl )-[1,2,4]triazol-1-yl]pyridine;
5-methanesulfonyl-2-[3-trifluoromethyl-5-(4-t-butylphenyl)-[1,2,4]tri azol-1-yl]pyridine;
5-methanesulfonyl-2-[3-trifluoromethyl-5-(4-cyanophenyl)-[1,2,4]tri azol-1-yl]pyridine;

5-methanesulfonyl-2-[3-trifluoromethyl-5-(4-aminophenyl)-[1,2,4]tri azol-1-yl]pyridine;
5-methanesulfonyl-2-[3-trifluoromethyl-5-(4-N-methylaminophenyl) -[1 ^^triazol-l-yljpyridine;
5-methanesulfonyl-2-[3-trifluoromethyl-5-(4-N,N-dimethylaminoph enyl)-[1,2,4]triazol-1-yl]pyridine;
5-methanesulfonyl-2-[3-trifluoromethyl-5-(3-methylphenyl)-[1,2,4]tr iazol-1-yl]pyridine;
5-methanesulfonyl-2-[3-trifluoromethyl-5-(3-trifluoromethylphenyl)-[1,2,4]triazol-1-yl]pyridine;
5-methanesulfonyl-2-[3-trifluoromethyl-5-(3-methoxyphenyl)-[1,2,4 ]triazol-1-yl]pyridine;
5-methanesuifonyl-2-[3-trifluoromethyl-5-(2,4-difluorophenyl)-[1,2J 4]triazol-1 -yl]pyridine;
5-methanesulfonyl-2-[3-trifluoromethyl-5-(2,5-difluorophenyl)-[1,2, 4]triazol-1 -yl]pyridine;
5-methanesulfonyl-2-[3-trifluoromethyl-5-(2,4,5-trifluorophenyl)-[1, 2,4]triazol-1 -yl]pyridine;
5-methanesulfonyl-2-[3-trifluoromethyl-5-(2,3-dichlorophenyl)-[1,2, 4]triazol-1 -yl]pyridine;
5-methanesulfonyl-2-[3-trifluoromethyl-5-(2,4-dichlorophenyl)-[1,2, 4]triazol-1-yl]pyridine;
5-methanesulfonyl-2-[3-trifluoromethyl-5-(3,5-difluorophenyl)-[1I2, 4]triazol-1 -yl]pyridine;
5-methanesulfonyl-2-[3-trifluoromethyl-5-(3,5-dimethoxyphenyl)-[1, 2,4]triazol-1-yl]pyridine;
5-methanesulfonyl-2-[3-trifluoromethyl-5-(2,4-dimethoxyphenyl)-[1, 2,4]triazol-1 -yl]pyridine;
5-methanesulfonyl-2-[3-trifluoromethyl-5-(3,4,5-trifluorophenyl)-[1, 2,4]triazol-1 -yl]pyridine;
5-methanesulfonyl-2-[3-trifluoromethyl-5-(2-fluoro-4-trifluoromethyl phenyl)-[1,2,4]triazol-1 -yl]pyridine;
5-methanesulfonyl-2-[3-trifluoromethyl-5-(2-chloro-4-nitrophenyl)-[ 1,2,4]triazol-1 -yl]pyridine;
5-methanesulfonyl-2-[3-trifluoromethyl-5-(2,4-dichloro-5-fluorophe nyl)-[1,2,4]triazol-1 -yljpyridine;
5-methanesulfonyl-2-[3-trifluoromethyl-5-(3-fluoro-4-methylphenyl) -[1,2,4]triazol-1-yl]pyridine;
2-(5-benzo[1,3]dioxol-5-yl-3-trifluoromethyl-[1,2,4]triazol-1 -yl)-5-m ethanesulfonyl pyridine;
3-[2-(4-methanesulfonylphenyl)-5-trifluoromethyl-2H-[1,2,4]triazol-3-yl]pyridine;
4-[2-(4-methanesulfonylphenyl)-5-trifluoromethyI-2H-[1,2,4]triazol-3-yl]pyridine;
5-cyclohexyl-1 -(4-methanesulfonylphenyl)-3-trifluoromethyl-1 H-[1, 2,4]triazole;
5-cyclohexen-1-yl-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1 H-[1,2,4]triazole;
4-(5-phenyl-3-trifIuoromethyl-[1,2,4]triazoi-1-yl)benzenesulfonamid e;
4-[5-(4-bromophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenes ulfonamide;
4-[5-(4-fluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl] benzenes ulfonamide;
4-[5-(3,4-difluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benze nesulfonamide;
4-[5-(4-chlorophenyl)-3-trifluoromethyl-[1,2,4]triazoI-1-yl]benzenes ulfonamide;
4-[5-(3,4-dichlorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benze nesulfonamide;
4-[5-(4-methoxyphenyl)-3-trifluoromethyl-[1I2,4]triazol-1-yl]benzen esulfonamide;
4-[5-(3,4-dimethoxyphenyl)-3-trifluoromethyl-[1,2,4]triazo!-1-yl]ben zenesulfonamide;
4-(5-p-tolyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfonamid e;
4-[5-(3,4-dimethylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benze nesulfonamide;
4-[5-(3-chloro-4-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl] benzenesulfonamide;
4-[5-(4-chlo,ro-3-methylphenyl)-3-trifluoromethyl-[1I2,4]triazol-1-yl] benzenesulfonamide;
4-[5-(3-chloro-4-methoxyphenyl)-3-trifIuoromethyl-[1,2,4]triazol-1-y IJbenzenesulfonamide;
4-[5-(4-chloro-3-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-y Ijbenzenesulfonamide;
4-[5-(3-fluoro-4-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]b enzenesulfonamide;
4-[5-(4-fluoro-3-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]b enzenesulfonamide;
4-[5-(3-fluoro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl ]benzenesulfonamide;
4-[5-(3,5-dichloro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol -1-yl]benzenesulfonamide;
4-[3-trifiuoromethyl-5-(4-trifluoromethylphenyl)-[1,2,4]triazol-1-yl]be nzenesulfonamide;
4-[3-trifluoromethyl-5-(4-ethoxyphenyl)-[1,2,4]triazol-1-yl]benzenes ulfonamide;
4-[3-trifluoromethyl-5-(4-trifluoromethoxyphenyl)-[1,2,4]triazol-1-yl] benzenesulfonamide;
4-[3-trifluoromethyl-5-(4-t-butylphenyl)-[1,2)4]triazol-1-yl]benzenes ulfonamide;
4-[3-trifluoromethyl-5-(4-cyanophenyl)-[1)2l4]triazol-1-yl]benzenes ulfonamide;
4-[3-trifluoromethyl-5-(4-aminophenyl)-[1,2,4]triazol-1 -yl]benzenes ulfonamide;
4-[3-trifluoromethyl-5-(4-N-methylaminophenyl)-[1,2,4]triazol-1-yl]b enzenesulfonamide;
4-[3-trifluoromethyl-5-(4-N,N-dimethylaminophenyl)-[1,2,4]triazol-1 -yl]benzenesulfonamide;
4-[3-trifluoromethyl-5-m-tolyl-[1,2,4]triazol-1-yl]benzenesulfonamid e;
4-[3-trifluoromethyl-5-(3-trifluoromethylphenyl)-[1,2,4]triazol-1 -yl]be nzenesulfonamide;
4-[3-trifluoromethyl-5-(3-methoxyphenyl)-[1,2,4]triazol-1-yl]benzen esulfonamide;
4-[3-trifluoromethyl-5-(2-bromophenyl)-[1,2,4]triazol-1-yl]benzenes ulfonamide;
4-[3-trifluoromethyl-5-(2-methoxyphenyl)-[1,2,4]triazol-1-yl]benzen esulfonamide;
4-[3-trifluoromethyl-5-(2,4-difluorophenylH1,2,4]triazol-1-yl]benze nesulfonamide;
4-[3-trifluoromethyl-5-(2,5-difluorophenyl)-[1,2,4]triazol-1-yl]benze nesulfonamide;
4-[3-trifIuoromethyl-5-(2,4)5-trifluorophenyl)-[1,2,4]triazol-1-yl]benz enesulfonamide;
4-[3-trifluoromethyl-5-(2,3-dichlorophenyl)-[1)2,4]triazol-1-yl]benze nesulfonamide;
4-[3-trifluoromethyl-5-(2,4-dichlorophenyl)-[1,2,4]triazol-1-yl]benze nesulfonamide;
4-[3-trifluoromethyl-5-(3,5-dimethoxyphenyl)-[1,2,4]triazol-1-yl]ben zenesulfonamide;
4-[3-trifluoromethyl-5-(2,4-dimethoxyphenyl)-[1,2,4]triazol-1-yl]ben zenesulfonamide;
4-[3-trifluoromethyl-5-(3,4,5-trifluorophenyl)-[1,2,4]triazol-1-yl]benz enesulfonamide;
4-[3-trifluoromethyl-5-(2-fluoro-4-trifluoromethylphenyl)-[1,2,4]triaz ol-1 -yl]benzenesu!fonamide;
4-[3-trifluoromethyl-5-(2-chloro-4-nitrophenyl)-[1,2,4]triazol-1-yl]be nzenesulfonamide;
4-[3-trifluoromethyl-5-(2,4-dichloro-5-fluorophenyl)-[1,2,4]triazol-1-yl]benzenesulfonamide;
4-[3-trifluoromethyl-5-(3-fluoro-4-methylphenyl)-[1,2,4]triazol-1-yl]b enzenesulfonamide;
4-(5-benzo[1,3]dioxol-5-yl-3-trifluoromethyl-[1,2,4]triazol-1 -yl)benz enesulfonamide;
4-(5-pyridine-3-yl-3-trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfo namide;
4-(5-pyridin-4-yl-3-trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfon amide;
4-(5-cyclohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfona mide;
4-(5-cyclohexen-1 -yl-3-trifluoromethyl-[1,2,4]triazol-1 -yl)benzenes ulfonamide;
5-methanesulfonyl-2-(5-phenyl-3-trifluoromethyl-[1,2,4]triazol-1-yl) pyridine;
2-[5-(4-bromophenyl)-3-trifluoromethyl-[1I2l4]triazol-1-yl]-5-metha nesulfonyl pyridine;
2-[5-(4-fluorophenyl)-3-trifluoromethyl-[1,2,4]triazoI-1-yl]-5-methan esulfonyl pyridine;
2-[5-(3,4-difiuorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-met hanesulfonyl pyridine;
2-[5-(4-chlorophenyl)-3-trifluoromethyl-[1,2,43triazo!-1-yl]-5-methan esulfonyl pyridine;
2-[5-(3,4-dichlorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-met hanesulfonyl pyridine;
5-methanesulfonyl-2-[5-(4-methoxyphenyl)-3-trifluoromethyl-[1I2,4 ]triazol-1 -yl]pyridine;
2-[5-(3,4-dimethoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-methanesulfonyl pyridine;
5-methanesulfonyl-2-(5-p-tolyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)p yridine;
2-[5-(3,4-dimethylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-me thanesulfonyl pyridine;
2-[5-(3-chloro-4-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1 -yl]-5-methanesulfonyl pyridine;
2-[5-(4-chloro-3-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-methanesulfonyl pyridine;
6-[5-(3-chloro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-y l]pyridine-3-sulfonic acid amide;
6-[5-(4-chloro-3-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-y l]pyridine-3-sulfonic acid amide;
6-[5-(3-fluoro-4-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]p yridine-3-sulfonic acid amide;
6-[3-trifluoromethyl-5-(4-trifluoromethylphenyl)-[1I2,4]triazol-1-yl]py ridine-3-sulfonic acid amide;
6-[3-trifluoromethyl-5-(4-ethoxyphenyl)-[1I2,4]triazol-1-yl]pyridine-3 -sulfonic acid amide;
6-[3-trifluoromethyl-5-(4-trifluoromethoxyphenyl)-[1,2,4]triazol-1-yl] pyridine-3-sulfonic acid amide;
6-[3-trifluoromethyl-5-(4-t-butylphenyl)-[1,2,4]triazol-1-yl]pyridine-3 -sulfonic acid amide;
6-[3-trifluoromethyl-5-(4-cynophenyl)-[1,2,4]triazol-1-yl]pyridine-3-s ulfonic acid amide;
G-lS-trifluoromethyl-S^-aminophenylHI^^triazol-l-yOpyridine-S -sulfonic acid amide;
6-[3-trifluoromethyl-5-(4-N-methylaminophenyl)-[1,2,4]triazol-1 -yl]p yridine-3-sulfonic acid amide;
6-[3-trifluoromethyl-5-(4-N,N-dimethylaminophenyl)-[1,2,4]triazol-1 -yl]pyridine-3-sulfonic acid amide;
6-[3-trifluoromethyl-5-m-tolyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide;
6-[3-trifluoromethyl-5-(3-methoxyphenyl)-[1,2,4]triazol-1-yl]pyridine -3-sulfonic acid amide;
6-[3-trifluoromethyl-5-(3-trif!uoromethylphenyl)-[1,2,4]triazol-1-yl]py ridine-3-sulfonic acid amide;
6-[3-trifluoromethyl-5-(2-bromophenyl)-[1,2,4]triazol-1-yl3pyridine-3 -sulfonic acid amide;
6-[3-trifluoromethyl-5-(2-methoxyphenyl)-[1,2,4]triazol-1-yl]pyridine -3-sulfonic acid amide;
6-[3-trifluoromethyl-5-(2,4-difluorophenyl)-[1,2,4]triazol-1-yl]pyridin e-3-sulfonic acid amide;
6-[3-trifluoromethyl-5-(2,5-difluorophenyl)-[1,2,4]triazol-1-yl]pyridin e-3-sulfonic acid amide;
6-[3-trifluoromethyl-5-(3,5-difluorophenyl)-[1,2,4]triazol-1-yl]pyridin e-3-sulfonic acid amide;
6-[3-trifluoromethyl-5-(2)4)5-trifluorophenyl)-[1,2,4]triazol-1-yl]pyridi ne-3-sulfonic acid amide;
6-[3-trifluoromethyl-5-(2-fluoro-4-trifluoromethylphenyl)-[1,2,4]triaz ol-1-yl]pyridine-3-sulfonic acid amide;
6-[3-trifluoromethyl-5-(2,4-dimethoxyphenyl)-[1,2,4]triazol-1-yl]pyri dine-3-sulfonic acid amide;
6-[3-trifluoromethyl-5-(3,4,5-trimethoxyphenyl)-[1,2,4]triazol-1-yl]py ridine-3-sulfonic acid amide;
6-[3-trifluoromethyl-5-(2-chloro-4-nitrophenyl)-[1,2,4]triazol-1-yl]pyr idine-3-sulfonic acid amide;
6-[3-trifluoromethyl-5-(2,4-difluoro-5-fluorophenyl)-[1,2,4]triazol-1-y l]pyridine-3-sulfonic acid amide;
6-[3-trifluoromethyl-5-(3-fluoro-4-methylphenyl)-[1,2,4]triazol-1-yl]p yridine-3-sulfonic acid amide;
2-[5-(4-fluoro-3-methylphenyl)-3-trifluoromethyl-[1I2,4]triazol-1-yl]-5-methanesulfonyl pyridine;
2-[5-(3-fluoro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl ]-5-methanesulfonyl pyridine;
2-[5-(3,5-dichloro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol -1-yl]-5-methanesulfonyl pyridine;
5-methanesulfonyl-2-((3-pyridinyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl))pyridine;
5-methanesulfonyl-2-((4-pyridinyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl))pyridine;
2-(5-cyclohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)-5-methanesulf onyl pyridine;
2-(5-cyclohexen-1 -yl-3-trifluoromethyl-[1,2,4]triazol-1 -yl)-5-methan esulfonyl pyridine;
6-(5-phenyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine-3-sulfonic acid amide;
6-[5-(4-bromophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3 -sulfonic acid amide;
6-[5-(4-fluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3-sulfonic acid amide;
6-[5-(3,4-difluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridin e-3-sulfonic acid amide;
6-[5-(4-chlorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-3 -sulfonic acid amide;
6-[5-(3,4-dichlorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridin e-3-sulfonic acid amide;
6-[5-(4-methoxyphenyl)-3-trifluoromethyl-[1I2,4]triazol-1-yl]pyridine -3-sulfonic acid amide;
e-fS^S^-dimethoxyphenyO-S-trifluoromethyl-fl^^ltriazol-l-yllpyri dine-3-sulfonic acid amide;
6-(5-p-tolyl-3-trifluoromethyl-[1I2,4]triazol-1-yl)pyridine-3-sulfonic acid amide;
6-[5-(3,4-dimethylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridi ne-3-suIfonic acid amide;
6-[5-(3-chloro-4-methylphenyl)-3-trifluoromethyl-[1,2,4]triazoi-1-yl] pyridine-3-sulfonic acid amide;
6-[5-(4-chloro-3-methy!phenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl] pyridine-3-sulfonic acid amide;
6-[5-(3-chloro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-y l]pyridine-3-sulfonic acid amide;
6-[5-(4-chloro-3-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-y l]pyridine-3-sulfonic acid amide;
6-[5-(3-fluoro-4-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]p yridine-3-sulfonic acid amide;
6-[5-(4-fluoro-3-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]p yridine-3-sulfonic acid amide;
6-[5-(3-fluoro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl ]pyridine-3-sulfonic acid amide;
6-[5-(3,5-dichloro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol -1-yl]pyridine-3-sulfonic acid amide;
6-(5-pyridin-3-yl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine-3-sufo nic acid amide;
6-(5-pyridin-4-yl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine-3-sufo nic acid amide;
6-(5-cyclohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine-3-sufon ic acid amide;
G^B-cyclohexen-l-yl-S-trifluoromethyl-tl^^triazol-l-ylJpyridine-S-sufonic acid amide;
2-methanesulfonyl-5-(5-phenyl-3-trifluoromethyl-[1,2,4]triazol-1-yl) pyridine;
5-[5-(4-bromophenyl)-3-trifluoromethyl-[1)2,4]triazol-1-yl]-2-metha nesulfonyl pyridine;
5-[5-(4-fluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-2-methan esulfonyl pyridine;
5-[5-(3,4-difluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-2-met hanesulfonyl pyridine;
5-[5-(4-chlorophenyl)-3-trifluoromethyl-[1I2,4]triazol-1-yl]-2-methan esulfonyl pyridine;
5-[5-(3,4-dichlorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-2-met hanesulfonyl pyridine;
2-methanesulfonyl-5-[5-(4-methoxyphenyl)-3-trifluoromethyl-[1,2,4 ]triazol-1-yl]pyridine;
methanesulfonyl pyridine;
2-methanesulfonyl-5-(5-p-tolyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)p yridine;
5-[5-(3,4-dimethylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-2-me thanesulfonyl pyridine;
5-[5-(3-chloro-4-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-2-methanesulfonyl pyridine;
5-[5-(4-chloro-3-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-2-methanesulfonyl pyridine;
5-[5-(3-chloro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-y l]-2-pyridine-2~sulfonic acid amide;
5-[5-(4-chloro-3-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-y l]pyridine-2-sulfonic acid amide;
5-[5-(3-fluoro-4-methyiphenyl)-3-trifluoromethyl-t1,2,4]triazol-1-yl]p yridine-2-sulfonic acid amide;
S-tS^-fluoro-S-methylphenyO-S-trifluoromethyl-tl^^triazol-l-yl]-2-methanesulfonyl pyridine;
5-[5-(3-fluoro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl ]-2-methanesulfonyl pyridine;
5-[5-(3,5-dichloro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol -1 -yl]-2-methanesuIfonyl pyridine;
5-(5-cyclohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)-2-methanesulf ony! pyridine;
5-(5-cyclohexen-1 -yl-3-trifluoromethyl-[1 ,2,4]triazol-1 -yl)-2-methan esulfonyl pyridine;
S^S-phenyl-S-trifluoromethyl-fl^^triazol-l-yOpyridine^-sulfonic acid amide;
-sulfonic acid amide;
5-[5-(4-f I uoro ph enyl )-3-trif I uoromethyl-[1 ,2 ,4]triazol- 1 -yl] py rid i n e-2-sulfonic acid amide;
5-[5-(3,4-difluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridin B-2-sulfonic acid amide;
5-[5-(4.chlorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridine-2 -sulfonic acid amide;
5-[5-(3,4-dichlorophenyl)-3-triftuoromethyl-[1,2,4]triazol-1-yl]pyridin e-2-sulfonic acid amide;
5-[5-(4-methoxyphenyl)-3-trifluoromethyl-[1,2I4]triazol-1-yl]pyridine -2-sulfonic acid amide;
5-[5-(3,4-dimethoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyri dine-2-sulfonic acid amide;
5-(5-p-tolyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine-2-sulfonic acid amide;
5-[5-(3,4-dimethylphenyl)-3-trifluoromethyl-[1,2,4]triazoI-1-yl]pyridi ne-2-sulfonic acid amide;
5-[5-(3-chloro-4-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl] pyridine-2-sulfonic acid amide;
5-[5-(4-chloro-3-methylphenyl)-3-trifluoromethyi-[1,2,4]triazol-1-yl] pyridine-2-sulfonic acid amide;
5-[5-(3-chloro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-y l]pyridine-2-sulfonic acid amide;
5-[5-(4-chloro-3-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-y l]-pyridine-2-sulfonic acid amide;
5-[5-(3-fluoro-4-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]p yridine-2-sulfonic acid amide;
5-[5-(4-fluoro-3-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]p yridine-2-sulfonic acid amide;
5-[5-(3-fluoro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl ]pyridine-2-sulfonic acid amide;
5-[5-(3,5-dichloro-4-methoxyphenyl)-3-trifluoromethyl-t1,2,4]triazol -1-yl]pyridine-2-sulfonic acid amide;
5-(5-pyridin-3-yl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine-2-sulfo nic acid amide;
5-(5-pyridin-4-yl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine-2-sulfo nic acid amide;
5-(5-cylcohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine-2-sulfo nic acid amide;
5-(5-cyclohexen-1-yl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridine-2-sulfonic acid amide;
3-methanesulfonyl-6-(5-phenyl-3-trifluoromethyl-[1,2,4]triazol-1-yl) pyridazine;
nesulfonyl pyridazine;
3-[5-(4-fluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-6-methan esulfonyl pyridazine;
S-tS^S^-difluorophenyO-S-trifluoromethyl-tl^^jtriazol-l-yO-e-met hanesulfonyl pyridazine;
3-[5-(4-chlorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-6-methan esulfonyl pyridazine;
3-[5-(3,4-dichlorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-6-met hanesulfonyl pyridazine;
3-methanesulfonyl-6-[5-(4-methoxyphenyl)-3-trifluoromethyl-[1,2,4 ]triazol-1 -yl] pyridazine;
3-[5-(3,4-dimethoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-6-methanesulfonyl pyridazine;
3-methanesulfonyl-6-(5-p-tolyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)p yridazine;
3-[5-(3,4-dimethylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-6-me thanesulfonyl pyridazine;
3-[5-(3-chloro-4-methylphenyl)-3-trifluorome%l-[1,2,4]triazoi-1-yl]-6-methanesulfonyl pyridazine;
3-[5-(4-chloro-3-methylphenyl)-3-trifluoromethyl-[1,2)4]triazol-1-yl]-6-methanesulfonyl pyridazine;
3-[5-(3-chloro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-y l]-6-methanesulfonyl pyridazine;
3-[5-(4-ch!oro-3-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-y l]-6-metha nesulfonyl pyridazine;
3-[5-(3-fluoro-4-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-6-methanesu!fonyl pyridazine;
3-[5-(4-fluoro-3-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-6-methanesulfonyl pyridazine;
3-[5-(3-fluoro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl ]-6-methanesulfonyl pyridazine;
3-[5-(3,5-dichloro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol -1 -yl]-6-methanesulfonyl pyridazine;
S-methanesulfonyl-e-CS-pyridin-S-yl-S-trifluoromethyl-fl^.^triazol-1-yl)pyridazine;
3-methanesulfonyl-6-(5-pyridin-4-yl-3-trifluoromethyI-[1,2,4]triazol-1-yl)pyridazine;
3-(5-cyclohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)-6-methanesulf onyl pyridazine;
3-(5-cyclohexen-1-yl-3-trifluoromethyl-[1,2,4]triazol-1-yl)-6-methan esulfonyl pyridazine;
6-(5-phenyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridazine-3-sulfoni c acid amide;
.6-[5-(4-bromophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine -3-sulfonic acid amide;
6-[5-(4-fluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine-3-sulfonic acid amide;
6-[5-(3,4-difluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-y!]pyridaz ine-3-sulfonic acid amide;
6-[5-(4-chlorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazine -3-sulfonic acid amide;
6-[5-(3,4-dichlorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyrida zine-3-sulfonic acid amide;
6-[5-(4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyridazi ne-3-sulfonic acid amide;
6-[5-(3,4-dimethoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyri dazine-3-sulfonic acid amide;
6-(5-p-tolyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridazine-3-sulfoni c acid amide;
6-[5-(3,4-dimethyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyrida zine-3-sulfonic acid amide;
6-[5-(3-chloro-4-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl] pyridazine-3-sulfonic acid amide;
6-[5-(4-chloro-3-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1 -yl] pyridazine-3-sulfonic acid amide;
6-[5-(3-chloro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-y l]pyridazine-3-sulfonic acid amide;
6-[5-(4-chloro-3-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-y l]pyridazine-3-sulfonic acid amide;
yridazine-3-sulfonic acid amide;
6-[5-(4-fluoro-3-methylphenyl)-3-trifluoromethyl-[1,2l4]triazol-1-yl]p yridazine-3-sulfonic acid amide;
6-[5-(3-fluoro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl ]pyridazine-3-sulfonic acid amide;
6-[5-(3,5-dichloro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol -1-yl]pyridazine-3-sulfonic acid amide;
6-(5-pyridin-3-yl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridazine-3-su Ifonic acid amide;
6-(5-pyridin-4-yl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridazine-3-su Ifonic acid amide;
6-(5-cyclohexyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridazine-3-sul fonic acid amide;
6-(5-cyclohexen-1-yl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyridazine-3-sulfonic acid amide;
5-methanesulfonly-2-(5-phenyl-3-trifluoromethyl-[1,2,4]triazol-1-yl) pyrimidine;
2-[5-(4-bromophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-metha nesulfonyl pyrimidine;
2-[5-(4-fluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-methan esulfonyl pyrimidine;
2-[5-(3,4-difluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-met hanesulfonyl pyrimidine;
2-[5-(4-chlorophenyl)-3-trifluoromethyl-[1I2,4]triazol-1-yl]-5-methan esulfonyl pyrimidine;
2-[5-(3I4-dichlorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-met hanesulfonyl pyrimidine;
5-methanesulfonyl-2-[5-(4-methoxyphenyl)-3-trifluoromethyl-[1I2,4 ]triazol-1 -yl]pyrimidine;
2-[5-(3,4-dimethoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-methanesulfonyl pyrimidine;
S-methanesulfonyl^S-p-tolyl-S-trifluoromethyKI^^Jtriazol-l-yOp yrimidine;

2-[5-(3,4-dimethylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-me thanesulfonyl pyrimidine;
2-[5-(3-chloro-4-methylphenyl)-3-trifluoromethyl-[l ,2,4]triazol-1 -yl]-5-methanesulfonyl pyrimidine;
2-[5-(4-chloro-3-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-methanesulfonyl pyrimidine;
2-[5-(3-chloro-4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1 -y l]-5-methanesulfonyl pyrimidine;
2-[5-(4-chloro-3-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-y l]-5-methanesulfonyl pyrimidine;
2-[5-(3-fluoro-4-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-methanesulfonyl pyrimidine;
2-(5-phenyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)pyrimidine-5-sulfoni c acid amide;
2-[5-(4-bromophenyl)-3-trifluoromethyl-[1,2I4]triazol-1-yl]pyrimidine -5-sulfonicacid amide;
2-[5-(4-fluorophenyl)-3-trifIuoromethyl-[1,2,4]triazol-1-yl]pyrimidine-5-sulfonicacid amide;
2-[5-(3,4-difluorophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyrimid ine-5-sulfonic acid amide;
2-[5-(4-chlorophenyl}-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyrimidine -5-sulfonicacid amide;
2-[5-(3,4-dichlorophenyl)-3-trifluoromethyI-[1,2,4]triazol-1-yl]pyrimi dine-5-sulfonic acid amide;
2-[5-(4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyrimidi ne-5-sulfonic acid amide;
2-[5-(3,4-dimethoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]pyri midine-5-sulfonic acid amide;
2-(5-p-tolyl-3-trifluoromethyl-[1,2I4]triazol-1-yl)pyrimidine-5-sulfoni c acid amide;
2-[5-(3,4-dimethylphenyl)-3-trifluoromethy!-[1,2,4]triazol-1-yl]pyrimi dine-5-sulfonic acid amide;
2-[5-(3-chloro-4-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl] pyrimidine-5-sulfonic acid amide;
2-[5-(4-chloro-3-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl] pyrimidine-5-sulfonic acid amide;
2-[5-(3-chloro-4-methoxyphenyl)-3-trifluoromethyl-[1,2I4]triazol-1-y l]pyrimidine-5-sulfonic acid amide;
2-[5-(4-chloro-3-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-y l]pyrimidine-5-sulfonic acid amide;
2-[5-(3-fluoro-4-methylphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]p yrimidine-5-sulfonic acid amide;
5-styryl-1 -(4-methanesulfonylphenyl)-3-trifluoromethyl-1 H-[1,2,4]tri azole; or
5-[2-(4-methoxyphenyl)-vinyl]-1-(4-methanesulfonylphenyl)-3-triflu oromethyl-1 H-[1,2,4]triazole.
According to another aspect of the present invention, there is provided an amidrazone derivative as an intermediate for the synthesis of the 1,2,4-triazole derivative of formula 1, as represented by formula 4:
Formula 4
wherein, R2, A, B, C, and D are as defined in formula 1 and n is an integer of 0 to 2.
According to another aspect of the present invention, there is provided a method for preparing a 1,2,4-triazole derivative of formula 1 or a non-toxic salt thereof, comprising reacting an amidrazone derivative of formula 4a with acyl chloride of formula 5 in the presence of base.
Formula 4a

(Formula 4a Removed)
Formula 5
wherein, R1f Ra, A, B, C, and D are as defined in formula 1 .
According to another aspect of the present invention, there is provided a method for preparing a 1 ,2,4-triazole derivative of formula 1 or a non-toxic salt thereof, comprising reacting an amidrazone derivative of formula 4b with acyl chloride of formula 5 in the presence of base and oxidizing the resultant compound with an oxidizing agent selected from the group consisting of magnesium monoperoxyphthalate hexahydrate (MMPP), m-chloroperoxybenzoic acid (MCPBA), and potassium peroxymonosulfate.
Formula 4b
(Formula 4b Removed)
wherein, Ra, A, B, C, and D is as defined in formula 1 and m is 0 or1.
The above mentioned reactions are preferably carried out in a polar solvent. Examples of the polar solvent include, but are not limited

to, dimethylformamide, 1,4-dioxane, dimethylsulfoxide,
N-methylpyrrolidinone, or m-xylene.
The reactions are preferably carried out at a temperature of-10 to 11CTC. A reaction time is determined depending on reactants. Generally, a reaction time of 10 minutes to 36 hours is required.
When the reactions are completed, the reaction resultants are extracted with water and an organic solvent such as ethyl acetate, dichloromethane, tetrahydrofuran, and ether, to remove salts. The crude extracts are purified by silica gel column chromatography to give the final products.
Bases to be used herein are organic bases or inorganic bases. The preferred organic bases are triethyl amine, trimethyl amine, tripropyl amine, pyridine, or imidazole. The preferred inorganic bases are sodium acetate, sodium hydroxide, sodium hydride, potassium hydroxide, sodium carbonate, or potassium carbonate. Pyridine is the most preferred.
The oxidative reaction is preferably carried out in dichloromethane in the presence of an oxidizing agent. The preferred oxidizing agent is MMPP, MCPBA, or potassium peroxymonosulfate.
According to another aspect of the present invention, there is provided a method for preparing a compound of formula 1 b, comprising reacting a compound of formula 1a with hydroxylamine or a salt thereof in the presence of a strong base and a Lewis acid.
Formula 1a
(Formula 1a Removed)
Formula 1b
(Formula 1b Removed)
wherein, RI, A, B, C, and D are as defined in formula 1.
According to another aspect of the present invention, there is provided a method for preparing a 1 ,2,4-triazole derivative of formula 1b or a non-toxic salt thereof, comprising reacting a compound of formula 6a with hydroxylamine or a salt thereof in the presence of a strong base and a Lewis acid and oxidizing the resultant compound using an oxidizing agent selected from the group consisting of MMPP, MCPBA, and potassium peroxymonosulfate.
Formula 6a
(Formula 6a Removed)
wherein, RI, A, B, C, and D are as defined in formula 1 and k is 1 orO.
The preferred hydroxylamine salt is hydroxylamine sulfate, hydroxylamine hydrochloride, hydroxylamine phosphate, hydroxylamine nitrate, or hydroxylamine sulfonate.
In order to prepare a compound in which R2 is a amino group in formula 1, at first, a compound of formula 1a or a compound of formula 6a is dehydrogenated in a solvent of tetrahydrofuran or ether at -78 to 80 °C in the presence of a strong base of alkyl lithium, aryl lithium, alkyl magnesium chloride, or aryl magnesium chloride. Then, the resultant compound is reacted with a Lewis acid such as alkylboron, arylboron, alkylaluminium, and arylaluminium at -78 to 80°C, followed by amination using hydroxylamine sulfate. Preferably, hydroxylamine sulfate is used
because when excess hydroxylamine sulfate is used, side reactions are minimal and the residual hydroxylamine sulfate and byproducts are easily removed upon extraction. After extraction, a crude extract is purified by column chromatography to produce a product having a desired sulfonamide group.
According to another aspect of the present invention, there is provided a method for preparing a compound of formula 4, comprising reacting a hydrazine derivative of formula 2 with trifluoroacetimidine of formula 3 in the presence of base.
Formula 2
(Formula 2 Removed)
Formula 3
wherein, R2, A, B, C, D, and n are as defined in formula 4.
The reaction is carried out in a solvent. The preferred solvent is methanol or a mixed solvent of methanol and tetrahydrofuran. The reaction is preferably carried out at a temperature of -10 to 66 °C. A reaction time is determined depending on reactants. Preferably, the reaction time is 10 minutes to 48 hours.
When the reaction is completed, the reaction resultant is extracted with water and an organic solvent such as ethyl acetate, dichloromethane, tetrahydrofuran, and ether, to remove salts. The crude extract is purified by silica gel column chromatography to give the compound of formula 4.
The base to be used herein is an organic base or an inorganic base. Preferably, the organic base is triethyl amine, trimethyl amine, tripropyl amine, pyridine, or imidazole. Preferably, the inorganic base is sodium acetate, sodium hydroxide, sodium hydride, potassium hydroxide,
sodium carbonate, or potassium carbonate. More preferably, triethylamine is used.
All crude products obtained from the above mentioned reactions are purified via a conventional post-treatment process, for example, chromatography and recrystallization to thereby give final products.
A method for preparing a compound of formula 1 is expressed by the following scheme 1:
Scheme 1
(Figure Removed)
wherein, R1, Ra, A, B, C, D, and n are as defined in the above.
As a hydrazine derivative to be used in the scheme 1, 4-hydrazinobenzenesulfonamide hydrochloride can be obtained from Maybridge (United Kingdom). Other hydrazine derivatives can be synthesized as it is or in the form of their hydrochlorides according to known methods [Tetrahedron Letters, vol 28, No 42, p4933, 1987; U.S. Patent No. 4,204,870; The Journal of Organic Chemistry, vol 56, No 16,
p4974, 1991; EP 1104759; and Tetrahedron, vol 48, No 21, p6791, 1989]. The synthesis methods of representative hydrazine derivatives are presented in Schemes 2 to 5. Scheme 2
(Figure Removed)
In Scheme 2, 4-bromo thioanisole is treated with magnesium to produce a Grignard compound. The Grignard compound reacts with a diazo compound and then hydrogen chloride to thereby produce a hydrochloride salt of hydrazine derivative.
Scheme 3
(Figure Removed)
In Scheme 3, a pyridine derivative reacts with hydrazine monohydrate to produce a 2-hydrazinopyridine derivative.
Scheme 4
(Figure Removed)
In Scheme 4, a nitro-substituted pyridine derivative is reduced to an amine-substituted pyridine derivative. Then, a hydrazine group is introduced to the amine-substituted pyridine derivative to produce a 3-hydrazinopyridine derivative.
Scheme 5
(Figure Removed)
In Scheme 5, a 2-hydrazinopyridazine derivative is prepared from 2,5-dichloro pyridazine according to a similar method as in the scheme 3.
In methods for preparing compounds of the present invention, reaction conditions such as types and amounts of solvent, base, and reactants are not limited to those as mentioned in the above. It is understood that a person of ordinary skill in the art can easily prepare compounds of the present invention through any combination of synthesis methods as described in the specification or as disclosed in known documents.
According to another aspect of the present invention, there is provided a pharmaceutical composition comprising a therapeutically
effective amount of a 1,2,4-triazol derivative or a non-toxic salt thereof as an active ingredient and a pharmaceutically acceptable carrier for the treatment of fever, pain, and inflammation.
The pharmaceutical composition comprises a compound of formula 1 or a non-toxic salt thereof when it is a selective inhibitor of cyclooxygenase-2. Therefore, the pharmaceutical composition can be used as an antipyretic, an analgesic, and an antiinflammatory agent, with minimal side effects.
Conventional nonsteroidal antiinflammatory agents non-selectively inhibit the prostaglandin synthesis enzymes, cyclooxygenase-1 and cyclooxygenase-2. Therefore, various side effects may occur.
On the other hand, a compound of formula 1 and a non-toxic salt thereof selectively inhibit cyclooxygenase-2. Therefore, the side effects of conventional nonsteroidal antipyretics, analgesics, and antiinflammatory agents can be reduced.
The pharmaceutical composition of the present invention comprises a compound of formula 1 and/or a non-toxic salt thereof and a pharmaceutically acceptable carrier or excipient. Therefore, the pharmaceutical composition may be used as a substitute for conventional nonsteroidal antiinflammatory agents. In particular, due to the reduction of the side effects of conventional nonsteroidal antipyretics, analgesics, and antiinflammatory agents, the pharmaceutical composition of the present invention is useful for treating patients with peptic ulcer, gastritis, regional enteritis, ulcerative colitis, diverticullitis, gastrorrhagia, or hypoprothrombinemia.
The pharmaceutical composition of the present invention can be used in all inflammatory diseases associated with pathological prostaglandin and is particularly appropriate for treating osteoarthritis and rheumatoid arthritis which require high dosage of nonsteroidal antiinflammatory agents.
The pharmaceutical composition of the present invention can be administered in the form of an adult dosage of 1 mg/day to 1000 mg/day of the compound of formula 1. An adequate dosage is determined depending on the degree of disease severity.
According to yet another aspect of the present invention, there is provided a pharmaceutical composition comprising a therapeutically effective amount of a 1,2,4-triazole derivative of formula 1 or a non-toxic
salt thereof and a pharmaceutically acceptable carrier for the treatment of cancers and dementia.
Recently, it was reported that nonsteroidal antiinflammatory agents are effective for the treatment of large intestine cancer [European Journal of Cancer, Vol 37, p2302, 2001], prostate cancer [Urology, Vol 58, p127, 2001], and dementia [Exp. Opin. invest. Drugs, Vol 9, p671, 2000]. Therefore, it is understood that the pharmaceutical composition of the present invention as a nonsteroidal antiinflammatory agent can also be used for the treatment of these diseases.
The pharmaceutical composition of the present invention can be administered in the form of an adult dosage of 1 mg/day to 1000 mg/day of the compound of formula 1 or a non-toxic salt thereof. An adequate dosage is determined depending on the degree of disease severity.
The pharmaceutical composition of the present invention may be administered in the form of tablet, foam tablet, capsule, granule, powder, sustained-release tablet, sustained-release capsule (a single unit formulation or a multiple unit formulation), intravenous and intramuscular injectable solution, infusion solution, suspension, or suppository, or in other suitable dosage forms.
Sustained-release pharmaceutical dosage forms contain active ingredients with or without an initial loading dose. They are wholly or partially sustained-release pharmaceutical dosage forms to release active ingredients in a controlled manner.
Preferably, the pharmaceutical composition is orally administered.
The pharmaceutical composition further comprises a pharmaceutically acceptable excipient and/or diluent and/or adjuvant in pharmaceutically effective amounts.
Examples of the excipient and adjuvant include gellatin, a natural sugar such as sucrose and lactose, lecitin, pectin, starch such as corn starch and amylose, cyclodextrin and cyclodextrin derivative, dextran, polyvinylpyrrolidone, polyvinyl acetate, Arabic gum, arginic acid, xylose, talc, salicylic acid, calcium hydrogen phosphate, cellulose, cellulose derivative such as methylcellulose, methoxypropyl cellulose, hydroxypropylmethyl cellulose, and hydroxypropylmethylcellulose phthalate, fatty acid having 12 to 22 carbon atoms, emulsifying agent, oil and fat, in particular, vegetable glycerol ester and polygiycerol ester of saturated fatty acids, monohydric alcohol, polyhydric alcohol, polyglycol
such as polyethylene glycol, aliphatic alcohol having 1 to 20 carbon atoms, or aliphatic saturated or unsaturated fatty acid ester having 2 to 22 carbon atoms with polyhydric alcohols such as glycol, glycerol, diethylene glycol, 1,2-propylene glycol, sorbitol, and mannitol.
Other suitable adjuvants include a disintegrating agent. Examples of the disintegrating agent include a cross-linked poiyvinylpyrrolidone, sodium carboxymethyl starch, sodium carboxymethyl cellulose, and microcrystalline cellulose. A coating agent which is conventionally used in this field may also be used. Examples of the coating agent include acrylic acid and/or methacrylic acid and/or an ester polymer or copolymer thereof, zein, ethyl cellulose, ethyl cellulose succinate, and Shellac.
Plasticizers suitable for the coating agent are citric ester and tartaric ester, glycerol and glycerol ester, or polyethylene glycol with different chain lengths.
A liquid composition such as solution and suspension is formulated in water or a physiological acceptable organic solvent such as alcohol and aliphatic alcohol.
The liquid pharmaceutical composition may further comprise a preservative such as potassium sofvate, methyl 4-hydroxybenzoate, and propyl 4-hydroxybenzoate, an antioxidant such as ascorbic acid, and a fragrant such as peppermint oil.
In addition, when the liquid pharmaceutical composition is formulated, a conventional solubiiizer or emulsifier such as poiyvinylpyrrolidone and polysolvate 80 may be used.
Other examples of suitable excipients and adjuvants are disclosed in Dr.H.P. Fielder, "Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik und angrenzende Gebiete" [Encyclopaedia of auxiliaries for pharmacy, cosmetics and related fields].
Hereinafter, the present invention will be described more specifically by examples. However, the following examples are provided only for illustrations and thus the present invention is not limited to or by them.
Example 1
N-(4-methylsulfanylphenyl)trifluoroacetamidrazone Formula 8

(Formula 8 Removed)
1.0 g (5.24 mmol) of 4-methylsulfanylphenylhydrazine hydrochloride was dissolved in 40 ml of a 1:1 mixed solvent of methanol and tetrahydrofuran and 0.80 ml (5.76 mmol) of triethylamine was added dropwise. The reaction mixture was stirred at room temperature for 30 minutes and 0.90 g (6.81 mmol) of 85% trifluoro acetimidine was added dropwise. The reaction mixture was stirred at room temperature for 24 hours. When the reaction was completed, water and ethyl acetate were added to the reaction mixture. The water layer was twice extracted with ethyl acetate. The combined organic layer was once washed with saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered under reduced pressure. The obtained crude product was purified by flash column chromatography (ethyl acetate/n-hexane = 2/8) to give 0.88 g of the title compound as a liquid (yield 67%).
1H-NMR (400MHz, CDCI3): 6 2.55 (s, 3H), 5.45 (s, 2H, br), 7.40 (d, 2H, J = 8.0 Hz), 7.60 (d, 2H, J = 8.0 Hz), 9.70 (s, 1H).
Example 2
N-(5-methanesulfonylpyridin-2-yl)trifluoroacetamidrazone Formula 9

(Formula 9 Removed)
205 mg (yield 54%) of the title compound as a solid was prepared in the same manner as in Example 1 except using 300 mg (1.34 mmol) of 5-methanesulfonylpyridin-2-yl hydrazine hydrochloride instead of 4-methylsulfanylphenylhydrazine hydrochloride.
1H-NMR (400MHz, CDCI3): 8 2.90 (s, 3H), 5.65 (s, 2H, br), 6.95 (dd, 1H, Ji = 9.0 Hz, J2 = 2.8 Hz), 7.80 (dd, 1H, J1 = 9.0 Hz, J2 = 2.0 Hz), 9.70 (d, 1H, J = 2.8 Hz), 9.75 (s, 1H).
Example 3
N-(2-methanesulfonylpyridin-5-yl)trifluoroacetamidrazone Formula 10
(Formula 10 Removed)
194 mg (yield 51%) of the title compound as a solid was prepared in the same manner as in Example 1 except using 300 mg (1.34 mmol) of 2-methanesulfonylpyridin-5-yl hydrazine hydrochloride instead of 4-methylsulfanylphenylhydrazine hydrochloride.
1H-NMR (400MHz, CDCI3): 6 3.35 (s, 3H), 5.65 (s, 2H, br), 6.95 (dd, 1H, Ji = 9.0 Hz, J2 = 2.8 Hz), 7.80 (dd, 1H, J-, = 9.0 Hz, J2 = 2.0 Hz), 9.70 (d, 1H, J = 2.8 Hz), 9.75 (s, 1H).
Example 4
N-(6-methanesulfonylpyridazin-3-yl)trifluoroacetamidrazone Formula 11

(Formula 11 Removed)
0.8 g (yield 64%) of the title compound as a solid was prepared in the same manner as in Example 1 except using 1.0 g (4.45 mmol) of 6-methanesulfonylpyridazin-3-yl hydrazine hydrochloride instead of 4-methylsulfanylphenylhydrazine hydrochloride.
1H-NMR (400MHz, CDCI3): 8 3.45 (s, 3H), 7.15 (s, 2H, br), 7.45
(d, 1H, J = 9.5 Hz), 8.00 (d, 1H, J = 9.5 Hz), 10.80 (s, 1H).
Example 5
N-(4-sulfonamidophenyl)trifluoroacetamidrazone Formula 12

(Formula 12 Removed)
0.9 g (yield 68%) of the title compound as a solid was prepared in the same manner as in Example 1 except using 1.0 g (4.47 mmol) of 4-hydrazinobenzenesulfonamide hydrochloride instead of 4-methylsulfanylphenylhydrazine hydrochloride.
1H-NMR (400MHz, CDCI3): 6 5.45 (s, 2H, br), 7.31 (s, 2H), 7.40 (d, 2H, J = 8.0 Hz), 7.60 (d, 2H, J = 8.0 Hz), 9.70 (s, 1H).
Example 6
1-(4-methylsulfanylphenyl)-5-p-tolyl-3-trifluoromethyl-1H-[1,2,4]tria zole
Formula 13
(Formula 13 Removed)
220 mg (0.88 mmol) of
N-(4-methylsulfanylphenyl)trifluoroacetamidrazone was dissolved in 5 ml of 1,4-dioxane and 0.08 ml (0.97 mmol) of pyridine was added dropwise.
The reaction mixture was stirred at room temperature for 10 minutes and 150 mg (0.97 mmol) of p-toluoyl chloride was added dropwise. The reaction mixture was stirred at the boiling point under reflux for 24 hours.
When the reaction was completed, the reaction mixture was cooled to room temperature and water and ethyl acetate were added thereto. The water layer was twice extracted with ethyl acetate. The combined organic layer was once washed with saturated sodium chloride solution and dried over anhydrous magnesium sulfate, and filtered under reduced pressure. The obtained crude product was purified by flash column chromatography (ethyl acetate/n-hexane = 2:8) to give 210 mg of the title compound as an oil (yield 65%).
1H-NMR (400MHz, CDCI3): 8 2.35 (s, 3H), 2.55 (s, 3H), 7.15 (d. 2H, J = 8.0 Hz), 7.20-7.30 (m, 4H), 7.45 (d, 2H, J = 8.0 Hz).
Example 7
1 -(4-methylsulfanylphenyl)-5-phenyl-3-trifluoromethyl-1 H-[1,2,4]tri
azole
Formula 14
(Formula 14 Removed)



210 mg (yield 71%) of the title compound as an oil was prepared in the same manner as in Example 6 except using 140 mg (0.97 mmol) of benzoyl chloride instead of p-toluoyl chloride. The title compound was used in the next step without further purification.
Example 8
5-(4-chlorophenyl)-1-(4-methylsulfanylphenyl)-3-trifluoromethyl-1H -[1,2,4]triazole
Formula 15
(Formula 15 Removed)
210 mg (yield 65%) of the title compound as an oil was prepared in the same manner as in Example 6 except using 170 mg (0.97 mmol) of 4-chlorobenzoyl chloride instead of p-toluoyl chloride. The title compound was used in the next step without further purification or identification.
Example 9
5-(4-bromophenyl)-1-(4-methylsulfanylphenyl)-3-trifluoromethyl-1H -[1,2,4]triazole
Formula 16
(Formula 16 Removed)
280 mg (yield 76%) of the title compound as an oil was prepared in the same manner as in Example 6 except using 213 mg (0.97 mmol) of 4-bromobenzoyl chloride instead of p-toluoyl chloride. The title compound was used in the next step without further purification or identification.
Example 10
1-(4-methylsulfanylphenyl)-5-(4-methoxyphenyl)-3-trifluoromethyl-1H-[1,2,4]triazole Formula 17
(Formula 17 Removed)
203 mg (yield 69%) of the title compound as an oil was prepared in the same manner as in Example 6 except using 165 mg (0.97 mmol) of p-anisoyl chloride instead of p-toluoyl chloride. The title compound was used in the next step without further purification or identification.
Example 11
5-(3-bromophenyl)-1-(4-methylsulfanylphenyl)-3-trifluoromethyl-1H -[1,2,4]triazole
Formula 18
(Formula 18 Removed)

280 mg (yield 76%) of the title compound as an oil was prepared in the same manner as in Example 6 except using 213 mg (0.97 mmol) of 3-bromobenzoyl chloride instead of p-toluoyl chloride. The title compound was used in the next step without further purification or identification.
Example 12
5-(3-chlorophenyl)-1-(4-methylsulfanylphenyl)-3-trifluoromethyl-1H -[1,2,4]triazole
Formula 19
(Formula 19 Removed)
182 mg (yield 72%) of the title compound as an oil was prepared in the same manner as in Example 6 except using 170 mg (0.97 mmol) of 3-chlorobenzoyl chloride instead of p-toluoyl chloride. The title compound was used in the next step without further purification or identification.
Example 13
5-(3-trifluoromethylphenyl)-1-(4-methylsulfanylphenyl)-3-trifluorom ethyl-1H-[1,2,4]triazole Formula 20
(Formula 20 Removed)

209 mg (yield 64%) of the title compound as an oil was prepared in the same manner as in Example 6 except using 202 mg (0.97 mmol)
of 3-trifluorometyl benzoyl chloride instead of p-toluoyl chloride. The title compound was used in the next step without further purification or identification.
Example 14
5-(2,4-dimethoxyphenyl)-1-(4-methylsulfanylphenyl)-3-trifluoromet hyl-1H-[1,2,4]triazole
Formula 21
(Formula 21 Removed)
188 mg (yield 54%) of the title compound as an oil was prepared in the same manner as in Example 6 except using 195 mg (0.97 mmol) of 2,4-dimeihoxybenzoyl chloride instead of p-toluoyl chloride. The title compound was used in the next step without further purification or identification.
Example 15
5-styryl-1 -(4-methylsulfanylphenyl)-3-trifluoromethyl-1 H-[1,2,4]tria
zole
Formula 22
(Formula 22 Removed)

in the same manner as in Example 6 except using 161 mg (0.97 mmol) of cynamoyl chloride instead of p-toluoyl chloride. The title compound was used in the next step without further purification or identification.
Example 16
5-[2-(4-methoxyphenyl)vinyl]-1-(4-methylsulfanylphenyl)-3-trifluoro methyl-1 H-[1,2,4]triazole Formula 23
(Formula 23 Removed)

189 mg (yield 55%) of the title compound as an oil was prepared in the same manner as in Example 6 except using 191 mg (0.97 mmol) of 4-methoxycynamoyl chloride instead of p-toluoyl chloride. The title compound was used in the next step without further purification or identification.
Example 17
5-(4-ethoxyphenyl)-1-(4-methylsulfanylphenyl)-3-trifIuoromethyl-1 ,2,4]triazole Formula 24
(Formula 24 Removed)

243 mg (yield 73%) of the title compound as an oil was prepared in the same manner as in Example 6 except using 181 mg (0.97 mmol) of 4-ethoxybenzoyl chloride instead of p-toluoyl chloride. The title compound was used in the next step without further purification or identification.
Example 18
5-(4-t-butylphenyl)-1-(4-methylsulfanylphenyl)-3-trifluoromethyl-1H -[1,2,4]triazole
Formula 25
(Formula 25 Removed)
282 mg (yield 82%) of the title compound as an oil was prepared in the same manner as in Example 6 except using 193 mg (0.97 mmol) of 4-t-butylbenzoyl chloride instead of p-toluoyl chloride. The title
compound was used in the next step without further purification or identification.
Example 19
. 5-(4-cyanophenyl)-1 -(4-methylsulfanylphenyl)-3-trifluoromethyl-1 H -[1,2,4]triazole
Formula 26
(Formula 26 Removed)
165'mg (yield 52%) of the title compound as an oil was prepared in the same manner as in Example 6 except using 163 mg (0.97 mmol) of 4-cyanobenzoyl chloride instead of p-toluoyl chloride. The title compound was used in the next step without further purification or identification.
Example 20
5-(4-nitro-2-chlorophenyl)-1-(4-methylsulfanylphenyl)-3-trifluorome thyl-1H-[1,2,4]triazole Formula 27
(Formula 27 Removed)
48 mg (yield 68%) of the title compound as an oil was prepared in the same manner as in Example 6 except using 213 mg (0.97 mmol) of 4-nitro-2-chlorobenzoyl chloride instead of p-toluoyl chloride. The title compound was used in the next step without further purification or identification.

Example 21
5-(3-chloro-4-methoxyphenyl)-1-(4-methylsulfanylphenyl)-3-trifluor omethyl-1 H-[1,2,4]triazole Formula 28
(Formula 28 Removed)
215 mg (yield 61%) of the title compound as an oil was prepared in the same manner as in Example 6 except using 200 mg (0.97 mmol)
of 3-chloro-4-methoxybenzoyl chloride instead of p-toluoyl chloride. The title compound was used in the next step without further purification or identification.
Example 22
5-benzo[1,3]dioxol-5-yl-1-(4-methylsulfanylphenyl)-3-trifluoromethy l-1H-[1,2,4]triazole Formula 29
(Formula 29 Removed)
206 mg (yield 59%) of the title compound as an oil was prepared in the same manner as in Example 6 except using 180 mg (0.97 mmol) of benzo[1,3]dioxol-5-yl carbonyl chloride instead of p-toluoyl chloride. The title compound was used in the next step without further purification or identification.
Example 23
4-[2-(4-methylsulfanylphenyl)-5-trifluoromethyl-2H-[1,2,4]triazol-3-yl]pyridine
Formula 30
(Formula 30 Removed)

121 mg (yield 41%) of the title compound as an oil was prepared in the same manner as in Example 6 except using 138 mg (0.97 mmol) of isonicotinyl chloride instead of p-toluoyl chloride. The title compound was used in the next step without further purification or identification.

Iazole
Example 24 1-(4-methanesulfonylphenyl)-5-p-tolyl-3-trifluoromethyl-1H-[1,2,4]tr
Formula 31
(Formula 31 Removed)
310 mg (0.89 mmol) of
1-(4-methylsulfanylphenyl)-5-p-tolyl-3-trifluoro-1 H-[1,2,4]triazole was dissolved in a mixed solvent of dichloromethane (10 ml) and methanol (2 ml) and 710 mg (1.16 mmol) of 80% MMPP was slowly added dropwise. The reaction mixture was stirred at room temperature for 8 hours.
When the reaction was completed, the reaction mixture was filtered. The filtrate was washed with sodium bicarbonate and saturated sodium chloride solution (1x each), dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained crude product was purified by flash column chromatography (ethyl acetate/n-hexane = 7:3) to give 308 mg (yield 91%) of the title compound as a solid.
1H-NMR (400MHz, CDCI3): 6 2.45 (s, 3H), 3.15 (s, 3H), 7.23 (d, 2H, J = 8.2 Hz), 7.38 (d, 2H, J = 8.2 Hz), 7.63 (d, 2H, J = 8.7 Hz), 8.03 (d, 2H, J = 8.7 Hz).
m.p.:176-178°C.
riazole
Example 25
1 -(4-methanesulfonylphenyl)-5-phenyl-3-trifluoromethyl-1 H-[1,2,4]t
Formula 32
(Formula 32 Removed)
283 mg (yield 86%) of the title compound as a solid was prepared
in the same manner as in Example 24 except using 300 mg (0.89 mmol)
of 1 -(4-methylsulfanylphenyl)-5-phenyl-3-trifluoro-1 H-[1,2,4]triazole
instead of
1 -(4-methylsulfanylpheny!)-5-p-tolyl-3-trifluoro-1 H-[1,2,4]triazole.
1H-NMR (400MHz, CDCI3): 8 3.15 (s, 3H), 7.42-7.48 (m, 2H), 7.50-7.55 (m, 3H), 7.63 (d, 2H, J = 8.6 Hz), 8.03 (d, 2H, J = 8.6 Hz).
m.p.: 153-154 °C.
Example 26 5-(4-chlorophenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-
1H-[1,2,4]triazole Formula 33
(Formula 33 Rmoved)
294 mg (yield 82%) of the title compound as a solid was prepared in the same manner as in Example 24 except using 330 mg (0.89 mmol) of
5-(4-chlorophenyl)-1 -(4-methylsulfanylphenyl)-3-trifluoro-1 H-[1,2,4]triazoi
einstead of
1-(4-methylsulfanylphenyl)-5-p-tolyl-3-trifluoro-1H-[1,2,4]triazole.
1H-NMR (400MHz, CDCI3): 6 3.15 (s, 3H), 7.40-7.50 (m, 4H), 7.60 (d, 2H, J = 6.7 Hz), 8.03 (d, 2H, J = 6.7 Hz).
m.p.: 190-192 °C.
Example 27
5-(4-bromophenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1H-[1,2,4]triazole Formula 34

(Formula 34 Removed)


365 mg (yield 92%) of the title compound as a solid was prepared in the same manner as in Example 24 except using 370 mg (0.89 mmol) of
5-(4-bromophenyl)-1 -(4-methylsulfanylphenyl)-3-trifluoro-1 H-[1,2,4]triazol
e instead of
1 -(4-methylsulfanylphenyl)-5-p-tolyl-3-trifluoro-1 H-[1,2,4]triazole.
1H-NMR (400MHz, CDCI3): 6 3.15 (s, 3H), 7.35 (d, 2H, J = 8.5 Hz), 7.50-7.60 (m, 4H), 8.03 (d, 2H, J = 6.3 Hz).
m.p.: 198-199 °C.

Example 28
1 -(4-methanesulfonylphenyl)-5-(4-methoxyphenyl)-3-trifluorometh yl-1H-[1,2,4]triazole Formula 35
(Formula 35 Removed)
300 mg (yield 85%) of the title compound as a solid was prepared in the same manner as in Example 24 except using 325 mg (0.89 mmol) of
1 -(4-methylsulfanylphenyl)-5-(4-methoxyphenyl)-3-trifluoro-1 H-[1,2,4]triaz
oleinstead of
1-(4-methylsulfanylphenyl)-5-p-tolyl-3-trifluoro-1H-[1,2,4]triazole.
1H-NMR (400MHz, CDCI3): 6 3.15 (s, 3H), 3.90 (s, 3H), 6.90 (d, 2H, J = 6.9 Hz), 7.35 (d, 2H, J = 6.9 Hz), 7.65 (d, 2H, J = 8.7 Hz), 8.03 (d, 2H, J = 8.7 Hz).
m.p.: 155-156 °C.
Example 29
5-(3-bromophenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1H-[1,2,4]triazole Formula 36
(Formula 36 Removed)
365 mg (yield 92%) of the title compound as a solid was prepared in the same manner as in Example 24 except using 370 mg (0.89 mmol) of
5-(3-bromophenyl)-1 -(4-methylsulfanylphenyl)-3-trifluoro-1 H-[1,2,4]triazol
einstead of
1-(4-methylsulfanylphenyl)-5-p-tolyl-3-trifluoro-1H-[1,2,4]triazole.
1H-NMR (400MHz, CDCI3): 6 3.15 (s, 3H), 7.35-7.72 (m, 6H), 7.92 (d, 2H, J = 8.7 Hz).
m.p.: 195-196 °C.
Example 30
5-(3-chlorophenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1H-[1,2,4]triazole Formula 37
(Formula 37 Removed)
326 mg (yield 91%) of the title compound as a solid was prepared in the same manner as in Example 24 except using 330 mg (0.89 mmol) of
5-(3-chlorophenyl)-1 -(4-methylsulfanylphenyl)-3-trifluoro-1 H-[1,2,4]triazol
einstead of
1 -(4-methylsulfanylphenyl)-5-p-toIyl-3-trifluoro-1 H-[1,2,4]triazole.
1H-NMR (400MHz, CDCI3): 8 3.11 (s, 3H), 7.00 (d, 1H, J = 9.0 Hz), 7.28 (m, 1H), 7.35 (d, 1H, J = 9.0 Hz), 7.62 (s, 1H), 7.64 (d, 2H, J = 9.2 Hz), 8.09 (d, 2H, J = 9.2 Hz).
m.p.: 188-190 °C.
Example 31
5-(3-trifluoromethylphenyl)-1-(4-methanesulfonylphenyl)-3-trifiuoro methyl-1H-[1,2,4]triazole Formula 38
(Formula 38 Removed)

340 mg (yield 88%) of the title compound as a solid was prepared in the same manner as in Example 24 except using 360 mg (0.89 mmol) of
5-(3-trifluoromethylphenyl)-1 -(4-methylsulfanylphenyl)-3-trifluoro-1 H-[1,2,
4] triazoleinstead of
1 -(4-methylsulfanylphenyl)-5-p-tolyl-3-trifluoro-1 H-[1,2,4] triazole.
1H-NMR (400MHz, CDCI3): 8 3.10 (s, 3H), 7.56 (m, 1H), 7.61-7.64 (m, 3H), 7.79 (d, 1H, J = 4.0 Hz), 7.86 (s, 1H), 8.09 (d, 2H, J = 8.8 Hz).
m.p.: 135-137 °C.
Example 32
5-(2,4-dimethoxyphenyl)-1-(4-methanesulfonylphenyl)-3-trifluorom ethyl-1H-[1,2,4]triazole Formula 39

(Formula 39 Removed)


357 mg (yield 94%) of the title compound as a solid was prepared in the same manner as in Example 24 except using 350 mg (0.89 mmol) of
5-(2,4-dimethoxyphenyl)-1-(4-methylsulfanylphenyl)-3-trifluoro-1H-[1,2,4]t
riazole instead of
1 -(4-methylsulfanylphenyl)-5-p-tolyl-3-trifluoro-1 H-[1,2,4]triazole.
1H-NMR (400MHz, CDCI3): 8 3.11 (s, 3H), 3.26 (s, 3H), 3.84 (s, 3H), 6.34 (d, 1H, J = 2.4 Hz), 6.66 (dd, 1H, J = 8.4 Hz, J = 2.4 Hz), 7.58 (d, 1H, J = 8.4 Hz), 7.69 (d, 2H, J = 8.8 Hz), 7.98 (d, 2H, J = 8.8 Hz).
m.p.: 110-1121C.

azole Example 33
5-styryl-1 -(4-methanesulfonylphenyl)-3-trifluoromethyl-1 H-[1,2
Formula 40
(Formula 40 Removed)

287 mg (yield 82%) of the title compound as a solid was prepoared in the same manner as in Example 24 except using 320 mg (0.89 n—imol) of 5-styryl-1-(4-methylsulfanylphenyl)-3-trifluoro-1 H-[1,2,4]triazole instead of 1-(4-methylsu!fanylphenyl)-5-p-tolyl-3-trifluoro-1 H-[1,2,4]triazole.
1H-NMR (400MHz, CDCI3): 8 3.15 (s, 3H), 6.83 (d, 1H, J = 15.9 Hz), 7.39-7.41 (m, 3H), 7.52-7.54 (m, 2H), 7.82 (d, 2H, J = 8.6 Hz), 8.01 (d, 1H, J = 15.9 Hz), 8.21 (d, 2H, J = 8.6 Hz).
m.p.: 168-170 °C.
Example 34
5-[2-(4-methoxyphenyl)vinyl]-1-(4-methanesulfonylphenyl)-3-trifluo romethyl-1 H-[1,2,4]triazole Formula 41
(Formula 41 Removed)
340 mg (yield 91%) of the title compound as a solid was prepared in the same manner as in Example 24 except using 378 mg (0.89 mmol) of
5-[2-(4-methoxyphenyl)vinyl]-1-(4-methylsulfanylphenyI)-3-trifluoromethyI
-1H-[1,2,4]triazole instead of
1 -(4-methylsulfanylphenyl)-5-p-tolyl-3-trifluoro-1 H-[1,2,4]triazole.
1H-NMR (400MHz, CDCI3): 8 3.17 (s, 3H), 3.85 (s, 3H), 6.75 (d, 1H, J = 15.9 Hz), 6.96 (d, 2H, J = 8.7 Hz), 7.50 (d, 2H, J = 8.7 Hz), 7.82 (d, 2H, J = 8.6 Hz), 7.95 (d, 1H, J = 15.9 Hz), 8.21 (d, 2H, J = 8.6 Hz).
Example 35
5-(4-ethoxyphenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1H-[1,2,4]triazole Formula 42
(Formula 42 Removed)
300 mg (yield 82%) of the title compound as a solid was prepared in the same manner as in Example 24 except using 337 mg (0.89 mmol) of
5-(4-ethoxyphenyl)-1 -(4-methylsulfanylphenyl)-3-trifluoromethyl-1 H-[1,2,4
jtriazole instead of
1 -(4-methylsulfanylphenyl)-5-p-tolyl-3-trifluoro-1 H-[1,2,4]triazole.
1H-NMR (400MHz, CDCI3): 8 1.45 (t, 3H, J = 7.0 Hz), 3.15 (s, 3H), 4.10 (q, 2H, J = 7.0 Hz), 6.91 (d, 2H, J = 8.9 Hz), 7.45 (d, 2H, J = 8.9 Hz), 7.65 (d, 2H, J = 8.7 Hz), 8.05 (d, 2H, J = 8.7 Hz).
m.p.: 152-154'C.
Example 36
5-(4-t-butylphenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1H-[1,2,4]triazole Formula 43
(Formula 43 Removed)
343 mg (yield 91%) of the title compound as a solid was prepared in the same manner as in Example 24 except using 348 mg (0.89 mmol) of
5-(4-t-butylphenyl)-1-(4-methylsulfanylphenyl)-3-trifluoromethyl-1H-[1,2,4]
triazole instead of
1 -(4-methylsulfanylphenyl)-5-p-tolyl-3-trifluoro-1 H-[1,2,4]triazole.
1H-NMR (400MHz, CDCI3): 6 1.30 (s, 9H), 3.15 (s, 3H),7.40-7.50 (m, 4H), 7.68 (d, 2H, J = 9.0 Hz), 8.08 (d, 2H, J = 9.0 Hz).
m.p.:81-82°C.Example 37
5-(4-cyanophenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1H-[1,2,4]triazole Formula 44
(Formula 44 Removed)

320 mg (yield 92%) of the title compound as a solid was prepared in the same manner as in Example 24 except using 320 mg (0.89 mmol) of
5-(4-cyanophenyl)-1 -(4-methylsulfanylphenyl)-3-tr'rfluoromethyl-1 H-[1,2,4]
triazole instead of
1 -(4-methylsulfanylphenyl)-5-p-tolyl-3-trifluoro-1 H-[1,2,4]triazole.
1H-NMR (400MHz, CDCI3): 6 3.15 (s, 3H), 7.64 (d, 2H, J = 8.8 Hz), 7.68 (d, 2H, J = 8.8 Hz), 7.75 (d, 2H, J = 8.7 Hz), 8.13 (d, 2H, J = 8.7 Hz).
m.p.:109-1inc.

Example 38
5-(4-nitro-2-chlorophenyl)-1-(4-methanesulfonylphenyl)-3-trifluoro methyl-1 H-[1,2,4]triazole Formula 45
(Formula 45 Removed)

314 mg (yield 79%) of the title compound as a solid was prepared in the same manner as in Example 24 except using 369 mg (0.89 mmol) of
5-(4-nitro-2-chlorophenyl)-1-(4-methylsulfanylphenyl)-3-trifluoromethyl-1H
-[1,2,4]triazole instead of
1 -(4-methylsulfanylphenyl)-5-p-tolyl-3-trifluoro-1 H-[1,2,4]triazole.
1H-NMR (400MHz, CDCI3): 8 3.15 (s, 3H), 7.51 (d, 2H, J = 8.6 Hz), 7.83 (d, 1H, J = 9.0 Hz), 7.97 (d, 2H, J = 8.6 Hz), 8.29 (d, 1H, J = 9.0 Hz), 8.32 (s, 1H).
Example 39
5-(3-chloro-4-methoxyphenyl)-1-(4-methanesulfonylphenyl)-3-triflu oromethyl-1 H-[1,2,4]triazole
Formula 46
(Formula 46 Removed)
319 mg (yield 83%) of the title compound as a solid was prepared in the same manner as in Example 24 except using 356 mg (0.89 mrnol) of
5-(3-chloro-4-methoxyphenyl)-1-(4-methylsulfanylphenyl)-3-trifluoromethy
l-1H-[1,2,4]triazole instead of
1 -(4-methylsulfanylphenyl)-5-p-to!yl-3-trifluoro-1 H-[1,2,4]triazole.
1H-NMR (400MHz, CDCI3): 8 3.15 (s, 3H), 3.95 (s, 3H), 6.90 (d, 1H, J = 8.6 Hz), 7.25 (dd, 1H, Ji = 8.6 Hz, J2 = 2.5 Hz), 7.75 (dd, 2H, Ji = 6.8 Hz, J2 = 2.0 Hz), 7.76 (d, 1H, J = 2.5 Hz), 8.08 (dd, 2H, J ,= 8.6 Hz, J2 = 2.0 Hz).
Example 40
5-benzo[1,3]dioxol-5-yl-1-(4-methanesulfonylphenyl)-3-trifluoromet hyl-1H-[1,2,4]triazole Formula 47

(Formula 47 Removed)


322 mg (yield 88%) of the title compound as a solid was prepared in the same manner as in Example 24 except using 337 mg (0.89 mmol) of
5-benzo[1,3]dioxol-5-yl-1 -(4-methylsulfanylphenyl)-3-trifluoromethyl-1 H-[1
,2,4]triazole instead of
1 -(4-methylsulfanylphenyl)-5-p-tolyl-3-trifluoro-1 H-[1,2,4]triazole.
1H-NMR (400MHz, CDCI3): 8 3.15 (s, 3H), 6.05 (s, 2H), 6.82 (d, 1H, J = 7.5 Hz), 6.97-7.02 (m, 2H), 7.65 (d, 2H, J = 8.6 Hz), 8.05 (d, 2H, J = 8.6 Hz).
Example 41
4-[2-(4-methanesulfonylphenyl)-5-trifluoromethyl-2H-[1,2,4]triazol-3-yl]pyridine
Formula 48
(Formula 48 Removed)

244 mg (yield 72%) of the title compound as a solid was prepared in the same manner as in Example 24 except using 299 mg (0.89 mmol)
of
4-[2-(4-methylsulfanylphenyl)-5-trifluoromethyl-2H-[1,2,4]triazo!-3-yl]pyridi
ne instead of
1 -(4-methylsulfanylphenyl)-5-p-tolyl-3-trifluoro-1 H-[1,2,4]triazole.
1H-NMR (400MHz, CDCI3): 6 3.15 (s, 3H), 7.45 (d, 2H, J = 6.0 Hz), 7.65 (d, 2H, J = 8.0 Hz), 8.10 (d, 2H, J = 8.0 Hz), 8.75 (d, 2H, J = 6.0 Hz).
m.p.: 180- 182 °C.
Example 42 4-(5-p-tolyl-3-trifluoromethyl-[1,2,4]triazol-1-yl)benzenesulfonamid
Formula 49
(Formula 49 Removed)
1 -(4-methanesulfonylphenyl)-5-p-tolyl-3-trifluoro-1 H-[1,2,4]triazole was dissolved in 2 ml of anhydrous tetrahydrofuran and the reaction temperature was adjusted to 0"C. 0.18 ml (0.54 mmol) of 3M solution of methyl magnesium chloride in tetrahydrofuran was added dropwise and the reaction temperature was raised to room temperature. The reaction mixture was stirred at that temperature for 3 hours. 0.9 ml (0.90 mmol) of 1M solution of tributylborane in tetrahydrofuran was added dropwise and refluxed for 18 hours. The reaction temperature was cooled to 0°C. Then, a solution in which 150 mg (1.34 mmol) of hydroxylarnine-O-sulfonic acid and 2.56 mg (3.20 mmol) of sodium acetic acid were dissolved in 2 ml of water was slowly added and the reaction mixture was stirred at room temperature for 3 hours. When the reaction was completed, water and ethyl acetate were added and stirred. Then, the resultant solution was three times extracted with ethyl acetate. The combined organic layer was once washed with saturated sodium chloride solution, dried over anhydrous magnesium sulfate, filtered under reduced pressure, and concentrated under reduced pressure. The obtained crude product was purified by flash column chromatography (ethyl acetate/n-hexane = 7/3) to give 63 mg (yield 52%) of the title compound as a solid.
1H-NMR (400MHz, DMSO-d5): 8 2.45 (s, 3H), 7.20 (d, 2H, J = 8.2 Hz), 7.35 (d, 2H, J = 8.2 Hz), 7.52 (s, 2H), 7.70 (d, 2H, J = 6.6 Hz), 7.98
(d, 2H, J = 6.6 Hz).
m.p.:245-247°C.
Example 43
4-[5-(4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzen e sulfonamide
Formula 50
(Formula 50 Removed)
68 mg (yield 53%) of the title compound as a solid was prepared in the same manner as in Example 42 except using 127 mg (0.32 mmol) of
1 -(4-methylsulfanylphenyl)-5-(4-methoxyphenyl)-3-trifluoro-1 H-[1,2,4]triaz
ole instead of
1 -(4-methanesulfonylphenyl)-5-p-to!yl-3-trifluoro-1 H-[1,2,4]triazole.
1H-NMR (400MHz, DMSO-d6): 8 3.85(s, 3H), 6.96 (d, 2H, J = 6.9 Hz), 7.45 (d, 2H, J = 6.9 Hz), 7.55 (s, 2H), 7.75 (d, 2H, J = 8.6 Hz), 7.95 (d, 2H, J = 8.6 Hz).
m.p.:251-253°C.

Example 44
4-[5-(4-bromophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzene sulfonamide
Formula 51
(Formula 51 Removed)

N-(4-sulfonamidophenyl)trifluoroacetamidrazone was dissolved in 5 mi of 1,4-dioxane and 0.08 ml (0.97 mmol) of pyridine was added dropwise. The reaction mixture was stirred at room temperature for 10 minutes and 212 mg (0.97 mmol) of 4-bromobenzoyl chloride was added dropwise. The reaction mixture was refluxed for 24 hours. When the reaction was completed, the reaction mixture was cooled to room temperature and water and ethyl acetate were added thereto. The water layer was twice extracted with ethyl acetate. The combined organic layer was once washed with saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered under reduced pressure. The obtained crude product was purified by flash column chromatography (ethyl acetate/n-hexane = 1/1) to give 208 mg (yield 53%) of the title compound as an oil.
1H-NMR (400MHz, CDCI3): 6 4.95 (br, s, 2H), 7.39 (d, 2H, J = 8.7 Hz), 7.58-7.62 (m, 4H), 8.05 (d, 2H, J = 8.7 Hz).
Example 45
2-[5-(4-bromophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-metha nesulfonyl pyridine Formula 52
(Formula 52 Removed)
130 mg (0.46 mmol) of
N-(5-methanesulfonylpyridin-2-yl)trifluoroacetamidrazone was dissolved in 5 ml of 1,4-dioxane and 0.04 ml (0.51 mmol) of pyridine was added dropwise. The reaction mixture was stirred at room temperature for 10 minutes and 115 mg (0.51 mmol) of 4-bromobenzoyl chloride was added dropwise. The reaction mixture was stirred at 110°C under reflux for 24 hours. When the reaction was completed, the reaction mixture was cooled to room temperature and water and ethyl acetate were added thereto. The water layer was twice extracted with ethyl acetate. The combined organic layer was once washed with saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered under reduced pressure. The obtained crude product was purified by flash column chromatography (ethyl acetate/n-hexane = 3:7) to give 107 mg (yield 52%) of the title compound as a solid.
1H-NMR (400MHz, CDCI3): 6 3.42 (s, 3H), 7.55 (d, 2H, J = 6.7 Hz), 7.70 (d, 2H, J = 6.7 Hz), 8.15 (d, 1H, J = 8.5 Hz), 8.65 (dd, 1H, J., = 8.5 Hz, J2 = 2.1 Hz), 8.95 (d, 1H, J = 2.1 Hz).
m.p.:143-145'C.
Example 46
2-[5-(4-methoxyphenyl)-3-trifIuoromethyl-[1.2.4]triazol-1-yl]-5-meth anesulfonyl pyridine
Formula 53
(Formula 53 Removed)
108 mg (yield 59%) of the title compound as a solid was prepared in the same manner as in Example 45 except using 87 mg (0.51 mmol)
of p-anisoyl chloride instead of 4-bromobenzoyl chloride.
1H-NMR (400MHz, CDCI3): 6 3.25(s, 3H), 3.85 (s, 3H), 6.90 (d, 2H, J = 6.8 Hz), 7.50 (d, 2H, J = 6.7 Hz), 7.95 (d, 1H, J = 8.5 Hz), 8.45 (dd, 1H, J, = 8.5 Hz, J2 = 2.1 Hz), 8.95 (d, 1H, J = 2.1 Hz), m.p.: 138- 139 °C.
Example 47
2-methanesulfonyl-5-[5-(4-bromophenyl)-3-trifluoromethyl-[1,2,4]tri azol-1-yl]pyridine Formula 54
(Formula 54 Removed)
N-(2-methanesulfonylpyridin-5-yl)trifluoroacetamidrazone was dissolved in 5 ml of 1,4-dioxane and 0.04 ml (0.51 mmol) of pyridine was added dropwise. The reaction mixture was stirred at room temperature for 10 minutes and 115 mg (0.51 mmol) of 4-bromobenzoyl chloride was added dropwise. The reaction mixture was stirred at 110°C under reflux for 24 hours. When the reaction was completed, the reaction mixture was cooled to room temperature and water and ethyl acetate were added thereto. The water layer was twice extracted with ethyl acetate. The combined organic layer was once washed with saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered under reduced pressure. The obtained crude product was purified by flash column chromatography (ethyl acetate/n-hexane = 3:7) to give 107 mg (yield 52%) of the title compound as a solid.
1H-NMR (400MHz, CDCI3): 6 3.42 (s, 3H), 7.55 (d, 2H, J = 6.7 Hz), 7.70 (d, 2H, J = 6.7 Hz), 8.22 (d, 1H, J = 8.5 Hz), 8.55 (dd, 1H, J, = 8.5 Hz, J2 = 2.1 Hz), 8.95 (d, 1H, J = 2.1 Hz). ' m.p.: 141-143°C.
Example 48
2-methanesulfonyl-5-[5-(4-methoxyphenyl)-3-trifluoromethyl-[1,2,4 ]triazol-1-yl]pyridine Formula 55
(Formula 55 Removed)
108 mg (yield 59%) of the title compound as a solid was prepared in the same manner as in Example 47 except using 87 mg (0.51 mmol) of p-anisoyl chloride instead of 4-bromobenzoyl chloride.
1H-NMR (400MHz, CDCI3): 6 3.25(s, 3H), 3.85 (s, 3H), 6.90 (d, 2H, J = 6.8 Hz), 7.50 (d, 2H, J = 6.7 Hz), 7.85 (d, 1H, J = 8.5 Hz), 8.35
(dd, 1H, Ji = 8.5 Hz, J2 = 2.1 Hz), 8.90 (d, 1H, J = 2.1 Hz). m.p.:136-137°C.
Example 49
3-[5-(4-bromophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-6-metha nesulfonyl pyridazine
Formula 56
(Formula 56 Removed)
310 mg (1.09 mmol) of
N-(6-methanesulfonylpyridazin-3-yl)trifluoroacetarnidrazone was
dissolved in 10 ml of 1,4-dioxane and 0.10 ml (1.20 mmol) of pyridine was added dropwise. The reaction mixture was stirred at room temperature for 10 minutes and 264 mg (1.20 mmol) of 4-bromobenzoyl chloride was added dropwise. The reaction mixture was stirred at 110°C under reflux for 24 hours. When the reaction was completed, the reaction mixture was cooled to room temperature and water and ethyl acetate were added thereto. The water layer was twice extracted with ethyl acetate. The combined organic layer was once washed with saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and filtered under reduced pressure. The obtained crude product was purified by flash column chromatography (ethyl acetate/n-hexane = 3:7) to give 220 mg (yield 45%) of the title compound as a solid.
1H-NMR (400MHz, CDCI3): 6 3.42 (s, 3H), 7.55 (d, 2H, J = 8.5 Hz), 7.62 (d, 2H, J = 8.5 Hz), 8.38 (d, 1H, J = 9.0 Hz), 8.45 (d, 1H, J = 9.0 Hz).
m.p.: 174-181TC.
Example 50
3-[5-(4-methoxyphenyl)-3-trifluoromethyl-[1.2.4]triazol-1-yl]-6-meth anesulfonyl pyridazine Formula 57
(Formula 57 Removed)
183 mg (yield 42%) of the title compound as a solid was prepared in the same manner as in Example 49 except using 205 mg (0.51 mmol) of p-anisoyl chloride instead of 4-bromobenzoyl chloride.
1H-NMR (400MHz, CDCI3): 6 3.42(s, 3H), 3.85 (s, 3H), 6.85 (d, 2H, J = 6.8 Hz), 7.55 (d. 2H, J = 6.8 Hz). 8.20 (d, 1H, J = 9.1 Hz), 8.35 (d, 1H,J = 9.1 Hz).
m.p.: 185-186 CC.
Experiments
1. Evaluation of selective COX-2 inhibitory activity
1) Method
In order to pharmacologically determine the selective COX-2 inhibitory activity, the percentages of the COX-1 and COX-2 inhibition of the compounds of the present invention illustrated in the Examples were measured by the following methods.
a. Assay for the COX-1 inhibitory activity using U-937 U-937 human lymphoma cells (Korean Cell Line Bank, Seoul, Korea, Accession Number: 21593) were cultured and centrifuged. The collected cells were diluted with HBSS (x1, Hank's balanced salt solution) to a concentration of 1 x 106 cells/ml. 1 ml of the dilute cell solution was placed into each well of 12-well plates. 5 ^i of 1 u M
solution of a test compound in DMSO and 5 fd of DMSO as a control were added to the wells. The wells were incubated in CO2 incubator at 371C for 15 minutes. Separately, 10 mM stock solution of arachidonic acid in ethanol was diluted ten times in ethanol to prepare 1 mM solution of arachidonic acid. Arachidonic acid acts as a substrate. 10 /^ of the 1 mM solution of arachidonic acid was added to each well and incubated at C02 incubator at 37"C for 30 minutes. The cell solution of each well was placed in a centrifuge test tube and centrifuged at 10,000 rpm at 4°C for 5 minutes. The concentration of PGE2 in the collected cells and the supernatant was quantified by means of a monoclonal kit (Cayman Chemicals). The percentages of PGE2 inhibition in a group of the test compound-treated cells in relation to a group of the DMSO-treated cells were calculated. Based on the calculated values, the COX-1 inhibitory activities were evaluated.
b. Assay for the COX-2 inhibitory activity using RAW 264.7 cell line
2 x 106 cells of RAW 264.7 cell line (Korean Cell Line Bank, Seoul, Korea, Accession Number: 40071) were inoculated into each well of 12-well plates. Each well was treated with 250 u M of aspirin and incubated at 37 °C for 2 hours. After the culture media were replaced with new culture media, the new culture media were treated with a test compound (10 nM) and incubated for 30 minutes. Then, each well was treated with interferon y (100 units/ml) and lipopolysaccharide (LPS, 100 ng/ml) and incubated for 18 hours. The culture media were transferred to another test tubes. The concentration of PGE2 was quantified by means of the EIA kit (Cayman Chemicals).
2) Test results
The test results are presented in Table 1 below. The percentages of the COX inhibition were calculated according to the following equation:
% Inhibition = (concentration of PGE2 in test compound-untreated sample - concentration of PGE2 in test compound-treated sample) / (concentration of PGE2 in test compound-untreated sample) x 100
(Table 1 Removed)
The in vitro test results about the percentages of the COX-1 and COX-2 inhibition are listed in Table 1.
As shown in Table 1, inhibition (%) ratios of COX-2 to COX-1 in
Examples 24 and 50 were equal to or higher than that in the reference,
Valdecoxib. This indicates that selective inhibition of COX-2 to COX-1
of the present compound is the same as or superior to that of the
reference. In particular, in the case of
1-(4-methanesulfonylphenyl)-5-(4-methoxyphenyl)-3-trifluoro-1H-[1,2,4]tri
azole of Example 28,
1 -(4-methanesulfonylphenyl)-5-(4-ethoxyphenyl)-3-trifluoro-1 H-[1,2,4]tria
zole of Example 35,
5-(3-chloro-4-methoxyphenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromet
hyl-1H-[1,2,4]triazole of Example 39,
5-bezo[1,3]dioxol-5-yl-1 -(4-methanesulfonylphenyl)-3-trifluoromethyl-1 H-[
1,2,4]triazole of Example 40,
4-[5-(4-bromophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzene
sulfonamide of Example 44,
2-[5-(4-bromophenyl)-3-trifluoromethyl-[1,2,4]triazol-1 -yl]-5-methanesulfo
nyl pyridine of Example 45, and
2-[5-(4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-methanesul fonyl pyridine of Example 46, the COX-2 inhibitory activities were remarkably enhanced in comparison with the reference. At the same time, the COX-1 inhibitory activities were the same as or lower than that of the reference. Therefore, it can be said that these compounds have excellent selectivities.
All the compounds of Examples except Examples 47, 49, and 50 exhibited the COX-2 inhibitory activities higher than the reference. Based on this result, it can be seen that the present compounds have reduced side effects due to enhanced selectivity and improved relief effects of fever, pain, and inflammation, compared to the reference.
2. Carrageenan-induced paw edema test in rats
1) Method
The day before the test date, rats were selected in each group so that the average body weight was as close as possible, and the rats were fasted by feed withdrawal prior to the test. At the test date, the rats were orally administered with the test compounds and a control material. After 1 hour, the volume (V0h) of a predetermined portion of the left hind foot of the rats was measured with a plethysmometer. 100 fd of 1% carrageenan solution was subcutaneously injected to the left hind foot of the rats using a syringe with 1 ml capacity. Three hours after the injection of the carrageenan, the volume (V3h) of the predetermined portion of the foot was again measured. The foot swelling variation (T3h -Toh) in a group of test compound-treated rats was compared with that of a group of control material-treated rats. With the supposition of 0% inhibition by the control (control material-treated rats), the inhibition percentage of edema of each test compound was determined.
2) Test results
(Table 2 Removed)
3) Evaluation
The in vivo test results of the percentage of COX inhibition are listed in Table 2.
As shown in Table 2, the % inhibition of the compounds in
Examples 27 to 46 against COX was almost the same as or much higher
than that of the Celecoxib. This indicates that the compounds of the
present invention have almost the same or higher COX inhibitory effects,
compared to the Celecoxib. In particular, in the case of
1 -(4-methanesulfonylphenyl)-5-(4-ethoxyphenyl)-3-trifluoro-1 H-[1,2,4]tria
zole of Example 35,
4-[5-(4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1 yl]benzenesulfon
amide of Example 43,
4-[5-(4-bromophenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]benzenesulfona
mide of Example 44, and
2-[5-(4-methoxyphenyl)-3-trifluoromethyl-[1,2,4]triazol-1-yl]-5-methanesul fonyl pyridine of Example 46, the COX inhibitory effects were remarkably improved in comparison with the Celecoxib.
In addition, all the compounds of Examples except Example 34
exhibited the same or higher COX inhibitory effects in comparison with the Celecoxib. Therefore, it can be seen that the compounds of the present invention have improved relief effects of fever, pain, and inflammation.
Industrial Applicability
As apparent from the above description, the present invention provides a 1,2,4-triazole derivative or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient. The pharmaceutical composition is effective in reducing fever, pain, and inflammation. In particular, as a result of reduction of the side effects of conventional nonsteroidal antiinflammatory agents, the pharmaceutical composition is useful for treating patients with peptic ulcer disease, gastritis, regional enteritis, ulcerative colitis, diverticullitis, gastrorrhagia, or hypoprothrombinemia.
While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it will be understood by those of ordinary skill in the art that various changes in form and details may be made therein without departing from the spirit and scope of the present invention as defined by the following claims.

WE CLAIM:
1. A method for preparing a 1,2,4-triazole derivative of formula 1 or a non-toxic salt thereof_ , comprising reacting an amidrazone derivative of formula 4b with acyl chloride of formula 5 in the presence of base such as herein described and oxidizing the resultant compound with an oxidizing agent selected from the group consisting of magnesium monoperoxyphthalate hexahydrate (MMPP), m-chloroperoxybenzoic acid (MCPBA), and potassium pcroxymonosulfate:
(Formula 1 Removed)
Formula 1
(Formula 4 Removed)
Formula 4b

(Formula 5 Removed)
Formula 5
wherein, Ri, R2, A, B, C, and D are as defined in claim 1 and m is o or 1.
2. A method for preparing a compound of formula 1b corresponding to a 1,2,4-triazole derivative of formula 1 as claimed in claim 1 or non-toxic salt
thereof, comprising reacting a compound of formula la with hydroxylamine or a salt thereof in the presence of a strong base such as herein described and a Lewis acid such as herein described:
Formula 1a
(Formula 1a Removed)
(Formula 1b Removed)
Formula Ib
wherein, R1, A, B, C, and D are as defined in claim 1.
3. A method for preparing a 1,2,4-triazole derivative of formula Ib corresponding to a 1,2,4-triazole derivative of formula 1 as claimed in claim 1 or a non-toxic salt thereof, comprising reacting a compound of formula 6a with hydroxylamine or a salt thereof in the presence of a strong base such as herein described and a Lewis acid such as herein described and oxidizing the resultant compound with an oxidizing agent selected from the group consisting of MMPP, MCPBA, and potassium peroxymonosulfate:
Formula 1b
(Formula 6a Removed)
Formula 6a
wherein, R1, A, B, C, and D are as defined in claim 1 and k is 0 or 1.
4. A method for preparing a compound of formula 4 as claimed in claim 3, comprising reacting a hydrazine derivative of formula 2 with trifluoroacetimidine of formula 3 in the presence of base such as herein described:
(Formula 2 Removed)
Formula 2
(Formula 3 Removed)
Formula 3
(Formula 4 Removed)
Formula 4
wherein, R2, A, B, C, and D are as defined in claim 1 and n is an integer of 0 to 2.
5. A method for preparing a 1,2,4-triazole derivative substantially as herein described with reference to the foregoing description, table and the accompanying examples.